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ABSTRACT 
Long-lived tissue-resident memory T cells (TRM) reside in nonlymphoid organs and can 
drive direct cytotoxicity, focal cytokine release and potent tissue-wide anti-infectious 
responses upon antigenic challenge. TRM cells poised to pathogenic responses have been 
identified in active and resolved psoriasis and mice models of allergic contact dermatitis 
(ACD). It is challenging to investigate the interactions between TRM cells and the local 
microenvironment in human tissues, and whether these cells promote disease in the absence 
of circulating T cells is less studied. This thesis focuses on the functional consequences of 
TRM cell activation inside the skin. 
PAPER I: TRM cells can provide protection from infections. The retention marker CD49a 
was correlated to both the epidermal location of skin TRM cells and their cytotoxicity. IL-15 
unleashed the killing capacities of CD8+CD103+CD49a+ T cells. The expression of CD49a 
in CD8+CD103+ skin T cells was associated with more IFN-γ release compared to 
CD8+CD103+CD49a-, which were conversely better IL-17 producers. CD49a expression 
delineated a CD8+ TRM cell specialization that was conserved in two inflammatory skin 
diseases psoriasis and vitiligo that were respectively enriched for CD8+CD103+CD49a- and 
CD8+CD103+CD49a+ TRM cells. 
PAPER II: Psoriasis is linked to overproduction of IL-17 and Type 1 interferon is 
implicated as a disease trigger in the early events transforming never-lesional psoriasis 
(NLP) into full-blown psoriasis. CCR6+CD49a- TRM cells poised towards IL-17 production 
were enriched in NLP, possibly due to microbe-induced epidermal chemotaxis. Activation 
of skin-resident T cells in NLP skin triggered Type 1 interferon tissue responses, potentially 
via IFN-γ-induced release of IFN-α in keratinocytes. As IFN-γ-potent TRM cells accumulate 
in NLP epidermis, our findings suggest that Type 1 interferon release in NLP could be 
driven by TRM cells. 
PAPER III: TRM cells poised to IL-17 and IL-22 production are retained in the epidermis in 
resolved psoriasis. In healthy and diseased skin, the activation of T cells within skin 
explants using the pan-T cell-activating antibody OKT-3 led to interferon-driven core-
response CXCL10 and CXCL9 expression. Additionally, IL-17-specific transcriptional 
signature was induced in resolved and active psoriasis sample, and the magnitude of this 
response was correlated with relapse shortly upon withdrawal of UVB treatment.  
PAPER IV: An upregulation of S100As transcripts persisted in the long-term in the 
epidermis of patients with resolved allergic contact dermatitis (ACD), indicating a disease 
scar. While inflammatory transcripts CXCL10, GZMB, and MMP12 were normalized after 
antigen exclusion for two months and two years, they were quickly induced in resolved 
epidermis upon exposure to the allergen. MMP12 was specifically upregulated in the 
epidermal compartment and codes for a protein capable of degrading the collagen IV that is 
a constituent of the skin basement membrane.  
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In conclusion, the TRM-driven tissue responses in human healthy and inflamed skin are 
highly compartmentalized and disease-specific. This concords with the functional 
heterogeneity of TRM cells themselves but also relies on their interplay with the stromal 
cells, which can help unveil pathogenic mechanisms in these relapsing-remitting 
inflammatory skin diseases. Preventing the TRM cell establishment or favoring their 
displacing by topical treatments could lead to significant improvements in the care of 
patients suffering from inflammatory diseases. 
PLAIN LANGUAGE SUMMARY 
The skin separates the human body from the environment. The epidermis is the very 
external layer of the skin. Specialized cells can differentiate aggressions that should trigger 
a reaction from harmless microbes and chemicals. However, this system can become 
defective, which leads to the development of inflammation, like the autoimmune disease 
psoriasis and the allergic disease allergic contact dermatitis. 
T cells are cells that can remember previously encountered dangers and mount disease-
driving immune responses. Psoriasis and allergic contact dermatitis are both relapsing-
remitting diseases in which T cells are present in the active phase of the disease and are 
targeted in current successful therapies. 
In psoriasis patients, T cells predisposed to the disease are present in skin areas that have 
never developed lesions so far. They can produce IL-17, a harmful protein blocked 
nowadays in biological therapies against psoriasis. The cells may be attracted to the 
normal-looking skin of psoriasis patients because of patient’s abnormal tissue-reaction to 
microbes. In active psoriasis, T cells accumulate in the skin and part of them remain after 
the inflammation disappears. Activating these dwelling T cells in patients’ biopsies led to 
molecular changes reminiscent of the active disease. The tissue-changes induced by the T 
cells could correlate to the remission time, from the moment a treatment is discontinued 
until a new one is started again. This finding is promising but needs to be confirmed in 
clinical trials.  
In allergic contact dermatitis, allergen avoidance is the only cure. Patient skin was sampled 
during the active allergy, then 2 months and finally 2 years after the disappearance of 
symptoms. Even after 2 years, the molecular state of the skin was not back to normal, 
indicating a “disease scar”. The T cells retained in the skin are likely to contribute to this 
scar. Molecular changes evocative of the active allergy and capable of disrupting the barrier 
between epidermis and the underlying dermis were observed in the skin upon T cell-
activation. This would enable blood cells to invade the upper layer and the skin and create 
symptoms. 
In sum, we have added arguments for the relevance of skin T cells in the development and 
recurrence of inflammatory skin diseases, by proposing mechanisms explaining how T cells 
can colonize the skin and start the inflammatory chain-reaction. Residing T cells could be 
used as predictors of relapse in the coming years. In the future, one aim is to be capable of 
displacing the disease-driving resident T cells thanks to topical treatments. 
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SAMMANFATTNING PA SVENSKA 
Huden är kroppens barriär mot omvärlden och skyddar mot omgivningens mikrober och 
kemikalier. I epidermis, den yttersta delen av huden, hittas flera olika sorters immunceller, 
bland annat T-celler, insprängda mellan keratinocyter. I huden kan immunceller utlösa en 
vävnadsreaktion för att skydda kroppen från mikrobiell invasion och skador. Vid kroniska 
inflammatoriska sjukdomar överreagerar hudens immunsystem mot ämnen/mikrober och 
skapar en lokal obalans i huden vilket i sin tur kan leda till sjukdomar som psoriasis eller 
allergisk kontakt-dermatit. Denna avhandling fokuserar på T-celler i huden som driver 
patologiska immunsvar. Psoriasis och kontakteksem är båda sjukdomar där T-celler 
ansamlas lokalt i huden och där patologi återkommer på samma ställen på huden upprepade 
gånger. Vid psoriasis är huden koloniserade av T-celler som producerar cytokinen IL-17 
som kan driva inflammation och därmed patologi. Keratinocyter hos psoriasispatienter 
reagerar på svamp med att producera cytokiner som attraherar IL-17-producerande celler 
till epidermis. Vid aktiv psoriasis ackumuleras T-celler lokalt i huden och en del av dem 
blir kvar efter att inflammationen läkt, trots att huden ser helt normal ut. Vid reaktivering 
svarar dessa kvarvarande T celler med IL-17 och kan på så sätt starta vävnadsinflammation 
igen. Studierna som presenteras i denna avhandling visar att reaktiverade T-celler som har 
kraftigt IL-17 svar, med SPRR2 och DEFB4A, korrelerar med snabbt återfall av psoriasis. 
Detta fynd kan testas i prospektiva kliniska studier och skulle kunna leda till en förbättring 
av nuvarande behandlingsstrategi. 
Vid kontekteksem är det enda sättet att bli symptomfri genom att undvika ämnet som 
orsakar allergin. Vi undersökte huden från patienter med aktiv sjukdom, efter två månader 
och slutligen två år efter aktiv sjukdom. I tidigare drabbad hud var genuttryck inte 
normaliserat efter två år, vilket indikerar att ett "sjukdomsärr" finns kvar i huden hos 
patienter med kontakteksem. T-cellerna som fanns kvar i huden kunde aktiveras när 
hudbiopsier stimulerades i kultur. De molekylära förändringar som sågs efter aktivering 
påminde om svaret man kan se i överhuden vid en aktiv allergisk reaktion. Det immunsvar 
som observerades har potential att öppna upp basalmembranet mellan överhuden och 
underliggande dermis. Således kan de långlivade T-cellerna i huden starta vävnads-
förändringar som gör att blodceller kan penetrera till epidermis och orsaka patologi. Dessa 
resultat öppnar upp för att använda målinriktade lokalbehandlingar vid behandling av 
eksem. I framtiden, hoppas vi kunna urskilja olika T-cells typer i huden, och hitta 
behandlingar där vi kan ersätta de skadliga cellerna med skyddande. 
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RESUME EN FRANCAIS 
La peau sépare le corps humain de son environnement. L'épiderme est la couche la plus 
externe de la peau où des cellules spécialisées peuvent différencier les agressions des 
expositions inoffensives. Quand ce système est défectueux, une inflammation survient, 
comment dans le psoriasis, une maladie auto-immune, ou l’eczéma de contact allergique 
(ECA), toutes deux des maladies récidivantes localement. Les lymphocytes T sont des 
cellules qui gardent en mémoire les dangers déjà rencontrés.  
Chez les patients atteints de psoriasis, des lymphocytes T prédisposés à la maladie sont 
présents dans les zones cutanées naïve, qui n'ont jamais encore développé de lésions (non-
lésionnelle). Ils peuvent produire de l'IL-17, une protéine nocive bloquée actuellement dans 
les thérapies biologiques contre le psoriasis. Ces lymphocytes résidents dans la peau non-
lésionnelle seraient attirés par une réaction tissulaire anormale aux microbes de la peau.  
Dans le psoriasis actif, les cellules T s’accumulent dans la peau puis diminuent en parallèle 
l’amélioration des symptômes. L’activation de ces lymphocytes T dans les biopsies de peau 
normalisée après une poussée conduit à des altérations moléculaires rappelant la maladie 
active. Cette signature moléculaire pourrait permettre de prévoir le temps de rémission, 
jusqu’à la mise en place d’un nouveau traitement. Cette découverte est prometteuse et doit 
être confirmée par des essais cliniques. 
Dans l’ECA, le seul remède consiste à éviter l’allergène. Nous avons examiné la peau des 
patients pendant l’allergie active, puis 2 mois et enfin 2 ans après la disparition des 
symptômes. Même après 2 ans, l'état moléculaire de la peau n'était pas revenu à la normale, 
indiquant une "cicatrice de la maladie". Des modifications moléculaires évocatrices de 
l'allergie active et susceptibles de rompre la barrière entre l'épiderme et le derme sous-
jacent ont été observées dans la peau lors de l'activation des lymphocytes T. Cela 
permettrait aux cellules sanguines d'envahir la couche supérieure de la peau et entrainer des 
symptômes. 
Les travaux de cette thèse argumentent en faveur de la pertinence des lymphocytes T 
cutanés dans le développement et la récurrence des affections cutanées inflammatoires, en 
proposant des mécanismes expliquant comment les lymphocytes T colonisent la peau et 
déclenchent une réaction en chaine aboutissant à l’inflammation. Les lymphocytes T 
résidents pourraient être utilisées comme prédicteurs de rechute dans les années à venir. A 
l'avenir, nous espérons pouvoir remplacer les lymphocytes T résidents responsables 
pathologiques grâce à des traitements topiques. 
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1 INTRODUCTION 
For the human skin to fulfill its many functions, the local immune system has to constantly 
balance between tolerance and inflammatory responses. At the cellular level, barrier 
immunology orchestrates many actors, including stromal cells. Among the resident immune 
cells in the skin, T cells are involved in the tissue response to infections and also in the 
pathogenesis of several inflammatory diseases. This thesis focuses on tissue-resident 
memory T cells (TRM cells) in the skin, and their function in common chronic T cell-driven 
dermatoses.  
1.1 THE HUMAN HEALTHY SKIN AND ITS IMMUNE SYSTEM 
1.1.1 The structure of the human skin 
The skin is one of the largest human organs and an essential barrier (Proksch et al., 2008), 
ensuring its own homeostasis and the protection of the internal tissues. It has to constantly 
sense the environment and elicit regulated tissue responses to ensure protection while 
safeguarding the tissue. 
The skin is formed by the epidermis and the dermis, which are separated by the basement 
membrane. The epidermis is an epithelium that lacks blood vessels and relies on the 
underlying dermis for nutrition. The predominant cell type is the keratinocyte. The 
thickness of the epidermis depends on the body site, and each layer has particular structural 
properties and shape (Figure 1) (Kolarsick et al., 2007). The basal layer is home to 
epidermal stem cells that allow for the constant regeneration of the epidermis. The further 
up from the basement membrane, the more differentiated keratinocytes are. Protruding 
between the keratinocytes, melanocytes are placed at the basement membrane and produce 
the pigment melanin. Hair follicles are epidermal structures diving into the dermis. They 
are important structures for tissue homeostasis that facilitate wound healing and interactions 
with the microbiota. The basement membrane is the lower frontier of the epidermis (Vidal, 
2013). It is not a porous membrane but an interlacement of anchoring molecules of 
collagens, glycoproteins, and proteoglycans produced mainly by the keratinocytes, 
attaching the epithelium to the underlying dermis (Figure 2). 
The dermis is a highly vascularized fibrous tissue populated by fibroblasts, containing 
matrix proteins such as collagens. It contains skin appendages, such as the sebaceous glands, 
sweat glands. Skin nerve endings are present in the dermis and up to the epidermis, and 
sense pain and temperature. The hypodermis lies under the dermis and contains the 
subcutaneous fat and larger blood vessels. 
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Figure 2 The skin basement membrane 
On the left, confocal microscopy was performed after cryosection of healthy human skin. On the right, 
schematic illustrating the composition of the basement membrane. 
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1.1.2 The skin external environment 
The skin is exposed to ultraviolet (UV) radiation daily, allowing for the production of 
Vitamin D that impacts the interplay between the skin and the microbiota (Agak et al., 2014) 
and locally the proliferation and differentiation of the keratinocytes (Svendsen et al., 1997). 
Furthermore, UV radiation affects melanocytes production of melanin that protects the skin 
from burns and cancers. However, UV radiation also has mutagenic effects and is involved 
in the generation of most of the skin cancers (Marrot et al., 2008; Reichrath, 2013). 
The last centuries with the era of industrialization present another challenge for the skin 
with steadily increasing contacts with chemicals and pollutants (Cetta et al., 1991; Rovira et 
al., 2019; Goldsmith 1996). The daily use of household and cosmetic products, and body 
hygiene products in modern society has also introduced repetitive contacts with many 
chemicals that may lead to irritant contact dermatitis, one of the most common occupational 
diseases (Carøe et al., 2014; Mowad et al., 2016). 
After birth, the skin is rapidly colonized by micro-organisms, in parallel to the arrival of 
additional immune cells (Scharschmidt et al., 2015). The composition of the skin 
microbiota is highly dependent on the body site and is well characterized when it comes to 
bacteria (Grice and Segre 2011; Grice et al., 2009). Increasing information on the fungal 
microbiota or mycobiota is now available (Belkaid and Segre 2014) but the viruses and 
archaea composition in normal skin remains obscure. Their interactions with the human 
body (Findley et al., 2013; Takemoto et al., 2014), and with other components of the biotas 
(Hannigan et al., 2015) is an area of intense work. Despite some major technical 
improvements, refined information about the strains and the potential inter-domain 
microbial interferences are yet challenging to obtain. With tight links to the innate and 
adaptive immune system (Thaiss et al., 2016), the skin microbiota could be considered as 
the most outer part of our immune system. 
1.1.3 Barrier immunology  
To safeguard the skin against infections and avoid excessive immunopathology, several 
cell-types can start an immune response and regulate inflammation, to fulfill the complex 
contextual functions of the skin. The focal communication system between cells in the skin 
relies on signaling molecules.  
Cytokines are soluble proteins that can mediate immune and inflammatory signals. The 
term interleukins initially referred to proteins mediating a signal between lymphocytes but 
they can also be detected by other cell types (Abbas et al., 2014). Cytokines that initiate 
chemotaxis have been named chemokines and are responsible for leukocytes migrating, 
both in homeostasis and to the sites of inflammation. Cytokines and chemokines can be 
produced by innate or adaptive immune cells and stromal cells. Some cytokines are blocked 
or activated to treat diseases, exemplified by TNF blockers in rheumatoid arthritis and 
interferons in C hepatitis. Damage-associated molecular patterns (DAMPS) or alarmins are 
additional signals comprised by small proteins or nucleic acids that are recognized by 
pattern recognition receptors (PRR). Several of the DAMPS proteins have cytokine-like 
functions and share common receptors. 
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There is no strict delimitation between cytokines, chemokines, alarmins, and antimicrobial 
peptides. For example, b-defensin 2 is an anti-microbial peptide with direct killing 
activity, produced in response to cytokines such as IL-17 or IL-6, it can bind to the 
chemokine receptor CCR6 and induce cell attraction. In Table 1, a subjective selection of 
signaling molecules relevant for this thesis is presented based on the following references: 
(Yang et al., 2017; Sebastiani et al., 2002; Griffith et al., 2014; Bromley et al., 2008). 
 
NAME SIZE 
(kDa) 
ALT. NAME RECEPTOR FUNCTIONS (NON EXHAUSTIVE) 
CXCL-9 14 Mig CXCR3 Attracts Th1, Th17, CD8, NK T cells 
CXCL-10 10  IP-10 CXCR3 Attracts Th1, Th17, CD8, NK T cells 
CXCL-8 11 IL-8 CXCR1 CXCR2 Attracts Neutrophils 
CCL-20  10  MIP-3α, 
LARC 
CCR6 Attracts Th17 cells. B cell and DC homing, antimicrobial 
CCL-4  10  MIP-1β CCR5 Attracts Macrophage and NK cell, guides encounter 
with DCs in lymph nodes 
IL-17 35  
 
IL-17RA (5 IL-
17R) 
Induction of proinflammatory cytokines, chemokines, 
and metalloproteases; recruitment and activation of 
neutrophils 
IFN-g 40-60  
 
IFNGR1/IFNGR2 Cytotoxic activity and TH1 differentiation; upregulation 
of MHC class I and II, induction of epithelial apoptosis 
in skin and mucosa 
IFN-a 15–21  
 
IFNAR Defense against viral infection, activation of naive T 
cells 
TNF 25  TNF-a TNFR1, TNFR2 Proinflammatory mediator and immunosuppressive 
mediator   
IL-15 18.6  
  
T-cell activation; proliferation and activation of NK 
cells 
IL-22 23  
 
IL-22R Pathogen defense; wound healing; tissue 
reorganization 
IL-13 10  
 
IL-13R1a1 
and IL-13R1a2 
Ig class switching, upregulation of MHC class II, 
activation of eosinophils and mast cells; defense 
against parasite infections 
IL-10 18  
 
IL-10R1/IL-10R2 Immunosuppressive effect through APCs or direct 
effects on Tcell subsets 
IL-9 14  
 
IL-9R T and mast cell growth factor; inhibition of TH1- 
cytokines; proliferation of CD81 T cells and mast cells; 
chemokine 
DEFB2 7  BD-2  CCR2, CCR6, 
TLR4 
Antimicrobial 
S100As 10-13  7: Psoriasin RAGE, TLR4 Leukocyte recruitment, pro-apoptotic 
LL-37 19  Cathelicidin FPRL1, TLR7,8,9, 
P2X7, EGFR, 
MrgX2, CXCR2 
Leukocyte recruitment 
Table 1 Interleukins (IL), chemokines (CXCL, CCL) and other signalling molecules 
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In vertebrates, the immune system is classically divided into innate and adaptive. The 
innate immune system is the most ancient, representing the first line of defence against 
aggressions at the body’s boundaries. 
The main cell types in the skin innate immune system are mast cells, eosinophils, basophils, 
neutrophils, innate lymphoid cells (ILCs), natural killer (NK) cells, macrophages and 
dendritic cells (Nestle et al., 2009; Artis and Spits 2015). Many cells from the innate 
immune systems are found in the skin at a steady state (Figure 3), in the dermis (Nestle et 
al., 2009), such as dendritic cells (DC): CD1c+, CD141+, myeloid DCs and plasmacytoid 
DCs (pDCs), as well as macrophages and CD14+ monocytes (Kashem et al., 2017). The 
dermis is vascularized and prone to a higher turnover of cells than the epidermis. 
Langerhans cells (LCs) are APCs seeded into the epidermis during the fetal stage and self-
renew locally during rodent life (Merad et al., 2002). When the skin gets attacked, LCs in 
the epidermis and DCs in the dermis are activated and migrate to lymph nodes to present 
the antigen to T cells.  
 
Figure 3 Immune cells in human skin 
Innate immune cells can recognize pathogens. At the cellular level, the recognition occurs 
through PPRs such as Toll Like Receptors (TLRs) and C-type lectin Receptors (CLRs), 
recognizing specific structures like bacterial flagella or chemical compound such as 
mannan, RNA, DNA (Murphy et al., 2012). The PRR expression decides what pathogens 
innate immune cells recognize. Extracellular pathogens can be recognized directly by 
macrophages and be degraded through phagocytosis. An important function of the innate 
immune system is the antigen presentation to the cells of the adaptive immune system, 
contributing also to the body defense (Owen et al.,, 2013). Antigen presentation relies on 
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Figure 3 Immune cells in human skin 
Innate immune cells can recognize pathogens. At the cellular level, the recognition occurs 
through PPRs such as Toll Like Receptors (TLRs) and C-type lectin Receptors (CLRs), 
recognizing specific structures like bacterial flagella or chemical compound such as 
mannan, RNA, DNA (Murphy et al., 2012). The PRR expression decides what pathogens 
innate immune cells recognize. Extracellular pathogens can be recognized directly by 
macrophages and be degraded through phagocytosis. An important function of the innate 
immune system is the antigen presentation to the cells of the adaptive immune system, 
contributing also to the body defense (Owen et al.,, 2013). Antigen presentation relies on 
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the expression of the loading molecules MHC (Major histocompatibility complex). MHC I 
is expressed by nucleated human healthy cells and can present short, intracellular peptides 
after an intracellular protein has gone through degradation in the proteasome. Cells that are 
infected or cancerous will then be detected and undergo apoptosis. MHC II is expressed by 
APCs and will present longer peptides after a protein has been phagocytosed and degraded 
in a lysosome. The MHC I aims at a direct killing of the presenting cell by CD8+ T cells 
and NK cells, while the APCs will migrate to the lymph node to present the peptide loaded 
on MHC II to CD4+ T cells. Exceptions exist and cross-presentation of extracellular MHC 
I-loaded peptide to CD8+ T cells is also possible (Abbas et al., 2014). Different skin APCs 
can promote diverse functions in the activated T cell (Kashem et al., 2016). Albeit highly 
efficient and powerful, the innate immune system lacks pathogen specificity and the classic 
definition of long-term memory. 
The canonical division between innate and adaptive immunology was questioned by the 
“trained memory” concept that originates from the observation that plants with no 
adaptive immune system and that had been exposed to attenuated microorganisms were 
protected for long periods against reinfections (Netea et al., 2011; Pereira et al., 2016). This 
“immune training” rather than immune memory relies partly on an enhanced recognition 
system with an increase of TLR expression leading to a state of alert in that given cell, but 
not a specific refined memory (Netea et al., 2011). These epigenetic changes can lead to 
cellular plasticity where exposure will trigger transcriptional profiling in a cell to optimize 
its function, (Alculumbre et al., 2018; Feinberg, 2007). In addition to this temporary 
cellular adaptation, epigenetic changes can be stable in a given cell for its entire life and 
even transmits to its progeny (Bonasio et al., 2010). Thus, although innate cells have no 
“memory” machinery, they can participate in the optimization of tissue protection. 
The adaptive immune system allows for the recollection of previous foreign encounters 
and improves immune response upon new challenges. T cells provide cellular immunity 
and B cells antibody-driven humoral immunity, together contributing to a defence system 
with specific recognition of antigens followed by quick killing or production of antigen-
specific antibodies. Both B and T cells have developed an advanced process of receptor 
generation, allowing for antigen-specificity.  
Many cell types and many molecular mechanisms take part in skin immunity and 
immunology. One challenge when studying skin immunology is the extraction of immune 
cells from their environment to phenotypically and functionally characterize them. The skin 
is a highly compartmentalized organ, 3D structure is essential and cell-to-cell interactions 
are tightly regulated (Mitsui et al., 2012; Shirshin et al., 2017). Thus, separating the cells 
from their environment can alter their characteristics and functions. Another sensitive issue 
is the identification of migratory vs resident immune cells that requires longitudinal 
information difficult to achieve in human research. Whole tissue analysis is complementary 
to the refined cellular characterizations and there is a need for techniques capable to get 
detailed cellular and molecular information inside the human skin itself, preferably in vivo.  
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1.2 SKIN T CELLS 
1.2.1 Introducing T cells 
In recent years, several new T cell subsets (Godfrey et al., 2015) have been characterized. 
Gamma-delta (gd) T cells and MAIT (mucosal-associated T cells) are of particular interest 
in the barrier organs. However, as these T cell types represent a minority of the human skin 
T cells this thesis focused on ab T cells (Cheuk et al., 2017; Toulon et al., 2009).  
1.2.1.1 Formation and activation of T cells 
Early T cell progenitors are generated in the bone marrow and maturate into T cells in the 
thymus. Each T cell harbors a T cell receptor (TCR), composed by heterodimers of either 
ab or gd chains. The ab TCR is dominant in humans (Haas 1993). The generation of the 
chains relies on the random rearrangement of V (variable), D (diversity, only for b chain) 
and J (joining), at the TRA locus for a chains and at the TRB locus for the b chain. The 
additional random deletion of nucleotides at the regions’ junctions leads to an almost 
endless diversity of specific TCR (Abbas et al., 2014; C. Y. Wang et al., 2016). The TCR is 
fixed for a given T cell during its whole life and transmits to its progeny.  
In the thymus, the progenitors are exposed to specific APCs named cortical thymic 
epithelial cells harboring self-peptides loaded on MHC I and II. This positive selection is 
ensuring that the T cells recognize a peptide-MHC complex. The second step takes place in 
the medulla, where medullary thymic epithelial cells will present antigens that are 
otherwise tissue-restricted, regulated by the transcription factor autoimmune regulator 
AIRE (Klein et al., 2014). The cells that recognize the MHC-self antigen complex with a 
high affinity will undergo apoptosis to avoid autoimmunity. The TCR associates with an 
additional CD247 protein, or ζ-chain and CD3 to form the TCR complex. At the end of the 
selection and maturation processes, T cells will carry a functional TCR and express either 
CD4 or CD8.  
CD4 is a glycoprotein of the immunoglobulin (Ig) superfamily. It is expressed on the 
surface of T cells, macrophages and DCs. CD4 interacts with the MHC II through one of its 
Ig domains (Abbas et al., 2014). T cells harboring CD4 are referred to as MHC II-restricted. 
The binding of CD4 allows for closer contact between the TCR and the MHC II and a 
subsequent stronger intracellular signal mediated by CD3 (Barber et al., 2006). CD8 is the 
molecule equivalent to CD4 for MHC I-restricted cells. It can also be expressed by Natural 
Killer (NK) cells and DCs. 
Moving forward, the mature, yet naive T cell leaves the thymus. If it encounters an APC 
presenting its cognate antigen in a secondary lymphoid organ, the TCR complex will bind 
to the MHC. The intracellular tail of CD3 has an immunoreceptor tyrosine-based activation 
motif (ITAM) that will be phosphorylated upon activation of the TCR complex and starts a 
cascade of signaling. To achieve activation, the naive T cell has to receive three signals. 
Signal 1 is the TCR-MHC recognition, signal 2 is the involvement of co-stimulatory 
molecules and signal 3 is the exposure to a favorable cytokine environment (Abbas et al., 
2014; Chen et al., 2013). In the absence of signal 2 and signal 3, anergy is likely to be the 
functional fate of the T cell. In rare cases, naïve T cells can be activated independently of a 
TCR-MHC interaction (Clement et al., 2011). A known case of this is the superagonist 
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monoclonal antibody against CD28 that triggered a life-threatening cytokine storm during a 
clinical trial (Hünig, 2012). A myriad of co-stimulatory and co-inhibitory molecules have 
been uncovered during the last decades (Chen et al., 2013). Co-stimulatory molecules 
deliver positive signals to T cells; co-inhibitory molecules deliver negative signals. For 
instance, when co-stimulatory CD28 expressed on T cell binds to CD80/CD86 (B7-1/B7-2) 
on a DC, it leads to T cell priming and DCs’ activation. To limit tissue damage and the 
inflammation, the co-inhibitory cytotoxic T lymphocyte antigen 4 (CTLA4) is expressed on 
the T cell and CD28 is downregulated. 
After activation, the T cell undergoes clonal expansion and drives an antigen-specific 
immune response. To study the T cell capacity to produce cytokines, a widely used proxy is 
based on Phorbol 12-myristate 13-acetate (PMA) that activates the protein kinase C, a 
protein activated downstream of the second signal (Figure 4). Ionomycin is often combined 
with PMA and also activates PKC (Chatila et al., 1989). It thus bypasses the TCR complex 
and triggers the T-cell activation. 
 
Figure 4 The three signals of naive T cell activation 
1.2.1.2 CD4+ and CD8+ T cells 
 The classification of “helper” CD4 subsets is based on the cytokines they produce (page 
19). The differentiation is influenced by the cytokines present in the environment (Figure 5) 
and on the expression of co-signaling molecules (Chen et al., 2013). Apart from cytokine 
production, CD4+ T cells support the maturation of B cells into plasma cells and memory B 
cells. They recognize extracellular antigens presented by APCs on MHC II (Abbas et al., 
2014). An important subtype of CD4+ T cells is regulatory T cells (Tregs). They are 
instrumental in the control of inflammation. They classically express the transcription 
factor FOXP3 and produce IL-10 and TGF-b, but these characteristics are not fixed and 
FOXP3 can be lost, with the cytokine production switching to pro-inflammatory ones 
(Zhou et al., 2009). The differentiation into Tregs will be controlled by the expression of 
certain co-inhibitory molecules. When expressed in conventional T cells, PD1 can promote 
the differentiation into induced Tregs (Chen et al., 2013).  
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The classification of different CD4+ T cell subsets is useful for in vitro-based studies but 
the system allows plasticity. Tissue inflammation can for instance modify their cytokine 
production (Cosmi et al., 2014). Thus, depending on the tissue state, overlap can be 
observed between Th2 and Th17 (Harrison et al., 2018), and FOXP3 can be induced in 
Th17 cells (Bovenschen et al., 2011; Huber et al., 2010).  
 
Figure 5 CD4+ T cell subsets 
 
The classical function of CD8+ T cells is the cytotoxicity. They recognize an intracellular 
antigen processed and presented on the MHC I and in certain situations, MHC I-loaded 
peptides from extracellular material that are cross-presented (Bevan 2006; Wehr et al., 
2019). CD8+ T cells kill target cells through the immune synapse, forming a hole in the 
membrane with Perforin and releasing Granzymes into the target cell that will undergo 
apoptosis (Talanian et al., 1997). They can as well produce cytokines such as IFN-γ, IL-2, 
TNF and TNF-related apoptosis-inducing ligand (TRAIL) among others. In nonlymphoid 
tissues, this can start potent antiviral tissue responses (Murphy et al., 2012; Ariotti et al., 
2014; Schenkel et al., 2013; Vassina et al., 2005).  
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1.2.1.3 T cell recruitment to the site of inflammation 
Both the APC’s organ of origin and the type of APC responsible for the T cell activation 
will determine the subsequent homing and functional fate of that T cell (Kashem et al., 
2017). The induction of tissue-specific chemokine receptors and homing molecules will 
guide T cells to the inflamed site (Campbell et al., 2002). For instance, the cutaneous 
lymphocyte antigen (CLA) is induced on T cells that will home to the skin (Clark et al., 
2006). Several other receptors are relevant for skin attraction such as CCR4, CCR10, CCR6 
and CCR8 (Homey et al., 2002; Campbell et al., 2007; Xia et al., 2014; Homey et al., 2000; 
Islam et al., 2011). The ligands of homing molecules can be expressed at a steady state, or 
produced by the tissue during inflammation, such as the chemokines CXCL-10 and CXCL-
9 that are produced by keratinocytes during viral infections and attract CXCR3+ T cells 
(Hickman et al., 2015; Iijima et al., 2015).  
1.2.1.4 Memory T cells subsets 
When the acute infection and inflammation subside, most of the effector T cells die off. 
Some will evolve into memory cells that trigger a quick and efficient immune response 
when the antigen is next encountered. In contrast to naïve T cells, the activation of memory 
T cells does not require three signals, as cell activation has been reported by single TCR-
MHC engagement or even by co-stimulatory signals without TCR commitment (Barski et 
al., 2017; Chen et al., 013). 
How the various subsets of T cells are generated during inflammation is only partly 
understood, and most of the current knowledge springs from mice (Akondy et al., 2017; 
Henning et al., 2018; Eidsmo et al., 2018). The different subsets of circulating memory 
cells consist classically of effector memory T cells (TEM CD45RA-CCR7-), central memory 
T cells (TCM CD45RA-CCR7+) that are capable of producing cytokines, and stem cell 
memory (TSCM CD45RA+CCR7+CD95+CD122+) that have no effector function but 
proliferate and self-renew (Kumar et al., 2018; Sallusto et al., 1999). A list of the T cells 
markers relevant in this thesis is presented in Table 2, based on the work of (Beura et al., 
2014; Wong et al., 2016; Owen et al., 2013; Groom et al., 2011). Of note, these markers 
were described according to bulk analysis of T cells, and single-cell techniques will allow 
the further division into functionally relevant subsets (Hughes et al., 2019).  
The subset considered responsible for the long-term memory were TCM as they persisted in 
the blood. A durable persistence in nonlymphoid tissues was later shown for TEM 
(Masopust 2001; Lanzavecchia and Sallusto 2005; Sallusto et al., 1999) and even 
occasionally for TCM (Gehad et al., 2018; Clark et al., 2012). The population of TEM found 
in the nonlymphoid tissues may also overlap with a more recently described subset of 
circulating T cells, peripheral memory cells (TPM) that go back and forth between the 
circulation and the nonlymphoid tissues (Gerlach et al., 2016) as shown in Figure 6. 
Migratory memory T cells (TMM) are CCR7+L-selectin- T cells identified in humans, that 
have an intermediary phenotype between TCM and TEM and can also enter peripheral tissues 
(Watanabe et al., 2015). The next part will focus on the T cells that are found in the skin.  
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Marker Function Naive Effector TCM TEM TRM 
L-selectin Homing to LN ++ - ++ - - 
CCR7 Migration of naive T cells to LN ++ - ++ +/- - 
CD44 cell adhesion and migration - +++ +++ +++ ++ 
CD69 S1PR1 inhibition - -/+ - - ++ 
CD103/aeb7  Integrin + - - - +++ 
S1P1 lymphocyte egress from lymphoid 
organs. 
++ ++ ++ ++ - 
CD45RA Receptor-mediated signaling ++ - - - - 
CD45RO Receptor-mediated signaling - ++ ++ ++ ++ 
CXCR3 Chemokine receptor for CXCL-9, 
CXCL-10 
- ++ ++ + ++ 
CD62L C-type lectin adhesion molecule ++ + ++ +/- - 
Table 2 T cell markers 
 
 
 
Figure 6 Memory T cell-subsets 
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1.2.2 Tissue resident memory (TRM) T cells 
1.2.2.1 T cells in the skin 
A localized tissue memory was suspected since the early 1900s, based on for instance the 
protection obtained from repeated superficial inoculations of fungi in the skin (De Lamater 
et al., 1938). The cells involved in this tissue memory remained unknown. Some 40 years 
ago, Bos et al., identified T lymphocytes in human skin and proposed the existence of a 
skin immune system (Bos et al., 1987). Skin mainly harbors abTCR T cells (Foster et al., 
1990), and their TCRs are not in balance with circulating T cells (Clark et al., 2006; Dunn 
et al., 2006). Microscopy and later on flow cytometry analysis showed that the vast 
majority of skin T cells are either CD4+ or CD8+ but CD4-CD8- abTCR T cells exist in 
human skin (Groh et al., 1989). Among the estimated 1 million T cells per cm2 that 
populate human skin (Clark et al., 2006), most are found in the dermis around the vessels 
and skin appendages (Bos et al., 1987). Epidermal T cells encounter for less than 10% of 
the skin T cells, with a memory/effector phenotype observed already in 1996 (Spetz, 
Strominger, and Groh-Spies 1996). Tregs are found in the human dermis, close to hair 
follicles. Few Tregs have shared TCR with other skin memory T cells (Rodriguez et al., 
2014), and their establishment is influenced by the skin microbiota (Naik 2012; 
Scharschmidt et al., 2017, 2015). 
1.2.2.2 Skin residency – CD8 T cells 
The idea of T cells dwelling in the skin progressed since early 2000. The hypothesis was 
first that the T cells detected in the skin were TEM, thus coming into the skin from blood 
vessels and leaving to scan lymph nodes for their cognate antigen (Von Andrian et al., 
2003). The observed absence of CCR7 expression prevented them to subsequently leave for 
the lymph nodes and suggested that these memory T cells could instead reside in the 
nonlymphoid tissues (Schenkel et al., 2014). The proof of residency was achieved in 
nonlymphoid organs in mice in 2001, and later on in skin (Gebhardt et al., 2009), using 
several imaginative methods (Figure 7).  
In parabiotic mice, the blood circulations of two mice are joined, the circulating cell-subsets 
equilibrate but the resident cells are retained in their original animal (Gaide et al., 2015). 
Other methods use skin grafts to compare which skin T cells equilibrate with the circulation 
and which remain in the skin (Glennie et al., 2015). Circulating cells can be depleted using 
female T cells transferred with male T cells before infection. The male circulating T cells 
will be rejected within 2 weeks but the epidermal skin-resident T cells are protected from 
eradication (Gebhardt et al., 2011b). Furthermore, cells crawling out of the skin were 
considered as resident and analyzed (Clark et al., 2006). In graft of human hands, long-
lived donor T cells persisted years after the graft (Eljaafari et al., 2006). In certain cases, 
TRM cells from the donor can be differentiated from the host through their expression of 
HLA (Lian et al., 2014). The duration of TRM persistence in human skin is not known. 
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Figure 7 Mice models of skin TRM cells 
The mice models allowed the characterization of CD8+ TRM cells as memory T cells 
establishing in nonlymphoid organs after infections or inflammation, and subsequently 
parked in tissues. Upon a new encounter of the antigen, they slow down their tissue 
crawling and proliferate locally. This was shown in mice in a contact hypersensitivity 
model, where T cells in skin were exposed externally to UV converted from GFP by violet 
during an antigenic challenge. They did proliferate locally but stayed absent from LN 5 
days after the challenge (Park et al., 2018). Conversely, a recent report using mice bought 
from pet stores or co-housed with them showed that CD8+ TRM cells could leave the skin 
after activation and populate secondary lymphoid organs (Beura et al., 2018), inviting to 
caution when extrapolating results obtained from mice with a controlled microbial 
environment. In 2019, new technological feat allowed the visualization of human CD8+ 
TRM cells within biopsies of human skin. This technical tour de force could confirm the 
crawling behavior and the localization of T cells under LCs and in the papillary dermis 
(Dijkgraaf et al., 2019).  
Several surface markers have been correlated to long-term skin dwelling in mice, and have 
been used for the identification of TRM cells in humans. First, most of the CD8+ TRM cells 
identified using parabiotic experiments express CD69. CD69 is expressed on both CD4+ 
and CD8+ TRM cells. CD69 down-regulates S1PR1 and mediates tissue retention (Skon et 
al., 2013; Shiow et al., 2006). Mediators like interferons can promote T cells retention 
through the upregulation of CD69, indicating that during viral challenges, the retention of 
cells in the tissue where they reside is prioritized (Shiow et al., 2006). Although it is a 
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useful residency marker for CD8+ TRM cells in the epidermis, its use in dermis requires 
caution (Watanabe et al., 2015; Collins et al., 2016). Other markers include the integrins 
CD103 and CD49a. CD103 is the α-chain of the αEβ7 integrin and CD49a is the α1 unit of 
the α1β1 integrin (Linda M Wakim et al., 2012; Gebhardt et al., 2009); they bind 
respectively to e-cadherin and collagen IV. In human skin, most T cells express either/or 
CD103 and CD69 (Watanabe et al., 2015). In CD8+ TRM cells of mice skin, the expression 
of CD69 is rather specific for the residency as skin CD8+CD69- TRM cells do recirculate 
(Hirai et al., 2019).  
1.2.2.3 CD4+ TRM cells in the skin 
Blood memory CD8+ T cells are a major antiviral player, and they can persist life-long 
while CD4+ T cell-memory slowly fades (Homann et al., 2001). Although the focus was 
first on CD8+ TRM cells, CD4+ T cells represent the majority of T cells in both human and 
mice skin, often located in clusters with DCs in the dermis (Collins et al., 2016; Cheuk et 
al., 2014). Additionally, in mice skin before any challenge, CD8+ T cells are virtually 
absent, and most CD4+ T cells were recirculating. More research started to focus on CD4+ 
TRM cells and showed that they are generated upon infectious challenges in mice after 
Candida albicans, protecting against subsequent challenges, and in human skin exposed to 
Leishmania major (Park et al., 2018; Glennie et al., 2015). After skin injection with herpes 
simplex virus (HSV) in mice, they accumulate in the dermis around hair follicles but not in 
the epidermis (Gebhardt et al., 2011b). CD4+ TRM cells also express the residency markers 
CD69 and CD103 but in human skin, a smaller proportion of CD4+ T cells express CD69 
and/or CD103 than CD8+ T cells (Boniface et al., 2018). This suggests that the CD4+ TRM 
cells might be more prone to recirculation. Indeed, despite the expression of TRM markers 
while in the skin, half of CD4+ TRM cells can lose the CD69 marker and recirculate, as 
shown with parabiotic setups and follow-up of cells after photo-conversion in the skin 
(Collins et al., 2016). In a humanized setup, recent work showed that CD4+ skin TRM cells 
from grafted human skin onto mice could downregulate CD69, migrate out of the skin and 
populate an artificial skin matrix that had been grafted elsewhere onto the mice, and where 
they could restore their initial phenotype (Klicznik et al., 2019).  
1.2.2.4 Compartmentalization  
An additional level of complication when studying TRM cells in human skin is the 
compartmentalization of skin. Mice skin differs from human skin in the density of hair 
follicles, the thinness of epidermis and a high proportion of gd T cells, to cite the most 
challenging differences. Mice skin is most often analyzed as a whole, without separating 
epidermis from dermis, even though the migratory properties of dermal TRM cells and 
epidermal TRM cells are likely to differ. The TRM phenotype in the dermis is less reliable 
than in the epidermis, with fewer cells expressing CD69 and CD103, both among CD4+ and 
CD8+ T cells (Watanabe et al., 2015). In 2013, Mackay et al., showed that in order to 
express CD103, CD8+ T cells had to first migrate to the epidermis, as the blockade of their 
migration upward to the epidermis decreased the number of CD103+ TRM cells (Mackay et 
al., 2013). The expression of residency marker correlates with the actual persistence, as 
dermal CD4+ TRM cells that express fewer markers equilibrate with the circulating 
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populations in long-term parabiotic mice experiments (Collins et al., 2016). In mice, CD8+ 
TRM cells are most often studied in the epidermis and CD4+ TRM cells in the dermis. This 
creates a confusion between the differences shown in CD8+ vs CD4+ TRM cells and the ones 
in epidermal vs dermal TRM cells in the literature.  
Table 3 exposes some of the differences between epidermal and dermal TRM cells, but does 
not consider variations between CD4 and CD8 subpopulations. Motility of epidermal and 
dermal TRM cells differ (Park et al., 2018), possibly depending on whether the stroma is 
tight or loose, and what cells are present. In that regard, the skin can be divided into three 
compartments: epidermis, papillary dermis and deeper dermis. T cells in the epidermis are 
the slowest. In the study by Park et al., the CD4+ T cells in the papillary dermis interacted 
more with DCs than their deep-dermis counterparts (Park et al., 2018).  
  
Epi - TRM Derm - TRM 
L-selectin Homing to LN  -  - 
CCR4 Homing to skin  ++  ++ 
CCR7 Migration of naive T cells to LN  -  - 
CD69 Tissue retention  +++  + 
CD103/aeb7  Integrin  +++  + 
CD45RO Memory T cells  +++  +++ 
CD45RA Naïve T cells  -  - 
CLA Homing  +++  +++ 
CCR6 Homing  ++  ++ 
Table 3 TRM cell-markers 
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1.2.3 The functions of skin TRM cells 
1.2.3.1 Skin protection against infections 
Protective functions of TRM cells against infections have been demonstrated in mice and 
strongly suggested in humans. TRM cells locally patrol the skin (Ariotti et al., 2012; S. L. 
Park, Zaid, et al., 2018). Upon new encounter of their antigen, they trigger strong tissue-
responses, as shown against viruses (Gebhardt et al., 2009) and place the tissue into a state 
of alertness (Ariotti et al., 2014), amplified by the stroma. TRM cells have been extensively 
studied using models of HSV infection in mice where HSV-specific CD8+ TRM cells 
colonized preferentially the epidermis (Gebhardt et al., 2009; Ariotti et al., 2012). Skin re-
infected by HSV could clear the infection, even without recruitment or circulating 
counterparts (as schematically represented in Figure 8). In humans, elegant HSV studies 
recruited subjects with recurrent genital herpes, and biopsies were taken at different 
timepoints on the genital mucosa. Using multimer staining, they could show the persistence 
of HSV-specific CD8+ T cells two months 
after a recurrence, close to the basement 
membrane (Zhu et al., 2007). These cells 
expressed GZMB, TNF and IFNG (Zhu et 
al., 2013). Data indicated that the local 
number of CD8+ T cells could predict 
whether an asymptomatic shedding or a 
clinical lesion would appear (Schiffer et al., 
2010). Additionally, asymptomatic HSV 
shedding was associated with an increased 
number of these specific T cells locally. 
Although this setting could not assess 
residency of the cells, it reinforced the idea 
that resident T cells could play an essential 
role in the peripheral immunity. 
 
TRM cells are less studied in non-viral 
microorganisms. Another type of 
microorganism infecting and/or colonizing 
the human skin is fungi. A resistance to 
reinfection could be obtained after a 
transcutaneous “lymphocyte sensitization” 
to dermatophytes in guinea pigs (Poulain et 
al., 1980). In humans, a similar 
phenomenon was also described by 
Greenbaum in 1924 (Greenbaum, 1924). 
Dermatophytes most often create 
superficial lesions in human subjects, but in 
case of deeper dermal infections, several 
immunological reactions are described. 
First, they can trigger distant lesions, 
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“psoriasis-like” inflammatory papules named dermatophytids in non-infected skin sites 
(Gianni et al., 1996). Dermatophytes can also create a Type IV hypersensitivity in case of 
persistent or recurrent infections and the intradermal inoculation of the preparation based 
on fungal products “trichophytin” then creates a delayed inflammation in the skin 
(Woodfolk et al., 1996; Chakrabarti et al., 1995). This reaction was used as an indicator of 
recent on ongoing infection with a dermatophyte some decades ago and was not species-
specific (Grappel et al., 1974). The “trichophytin” reaction persisted up to three years after 
the infection cleared. These findings strongly suggest the implication of memory T cells 
ensuring a long-term memory in the skin, although TRM cells have not been described yet in 
this setting. Additionally, it was shown that CD4+ TRM cells can provide tissue protection 
against the opportunistic pathogen C. albicans (Park et al., 2018; Roth et al., 1988). TRM 
cells are thus implicated in skin reaction to a wide range of microorganisms. 
1.2.3.2 Protection against cancerous cells 
TRM cells are perfectly placed in the epidermis to be major player in the control of skin 
neoplasms, both melanoma but also basal cell carcinoma and squamous cell carcinoma. It is 
sound immunological planning that TRM cells preferentially localize at the basement 
membrane, since access to the vessels is critical to the tumor egress. TRM cells have been 
implicated in the prevention of melanoma in a mice model of vitiligo where the skin TRM 
cells specific for melanocytes procured protection against subsequent melanoma 
development (Malik et al., 2017). Additionally, the induction of TRM cells in the skin of 
mice upon vaccination was shown to inhibit melanoma growth locally (Gálvez-Cancino et 
al., 2018). In the early stage of the tumor as well, TRM cells were identified as critical 
epidermal players to limit the development of invasive tumor (Park et al., 2018). This study 
provided an explanation to clinical observation of melanoma relapsing sometimes decades 
after the first tumor was excised (Shen et al., 2000). In established cancers, TRM cells 
infiltrating the tumors is a booming area, and in melanoma T cells with TRM phenotype 
were identified in 2016 in human tissue (Boddupalli et al., 2016). 
1.2.3.3 Effector functions 
So how do the TRM cells provide local protection? In 2008, Wakim et al., proved the 
concept of T cell local proliferation in nonlymphoid tissue. The proliferation of CD8+ 
tissue-resident T cells was shown possible in tissues upon encounter of their cognate 
antigen, with the participation of recruited CD4+ T cells and DCs (Wakim et al., 2008). 
Additionally, they showed that newly-recruited CD8+ T cells could also proliferate on-site 
(Wakim et al., 2014). Not strictly physiological, these proof-of-concept experiments were 
done on dorsal root ganglia grafted on kidneys and strongly suggested that resident T cells 
were capable of unleashing a T cell-driven response in their homing tissue. At the 
molecular level, cytokine production and cytotoxicity are key functions of T cells. Flow 
cytometry and later on transcriptome studies showed that both CD4+ and CD8+ TRM cells in 
human and mice skin are potent producers of cytokines like IFN-g, IL-2 granzymes and 
TNF, among others (Watanabe et al., 2015; Beura et al., 2019). Additionally, the 
production of cytokines differs depending on the CD103 marker expression with CD103 
associated to increased IL-17 an IL-22 production in human skin (Watanabe et al., 2015; 
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Kurihara et al., 2019). The transcriptome of human skin TRM cells, both CD8+ and CD4+ 
has been published in recent years and emphasized the differences between circulating and 
skin T cells (Li et al., 2016; Mackay et al., 2013), as well as between epidermal and dermal 
cells (Cheuk et al., 2017). CD4+ and CD8+ subsets of TRM cells are often studied as if they 
were homogeneous subsets but single-cell omics are bringing a well-needed level of 
complexity to identify new functional subsets (Hughes et al., 2019).  
1.2.3.4 Tissue responses 
CD8+ and CD4+ TRM cells can trigger quick tissue-wide responses when they reencounter 
their antigen in epithelia (Ariotti et al., 2014; Schenkel et al., 2013; Beura et al., 2019). For 
instance, upon reactivation of herpes-specific CD8+ TRM in the skin of mice, or exposure to 
herpes peptide, the full-thickness skin transcriptome shows upregulation of pro-
inflammatory signals as early as 3 hours after the challenge (Ariotti et al., 2014). The signal 
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al., 2013; Nograles et al., 2008). Apart from stromal cells, TRM cells are likely to influence 
other cells. For instance, mice devoid of CD4+ TRM cells have impaired DC maturation 
compared to mice with CD4+ TRM cells (Beura et al., 2019).  
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responses directed toward a tissue challenge. Upon local recall, TRM cells engage in focal 
interactions with the tissue’s other immune and stromal cells, providing anti-infectious and 
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The cellular origin of TRM cells in humans is not known, but several reports in mice indicate 
that these cells derive from effector cells that enter the tissue after the encounter of their 
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mice were protected against the actual HSV (Shin et al., 2012). Locally, the expression of 
CXCR3 by T cells is required to guide them to virally infected cells (Hickman et al., 2015), 
independently of whether their cognate antigen was present or not. On the other hand, 
antigenic exposure improves the establishment of TRM cells in the skin with enhanced 
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expression of CD103 and CD69 and potentializes their capacities to further recruit immune 
cells upon new antigenic challenge (Schenkel et al., 2013). Additionally, an antigen-
dependent competition in the inflamed tissue shapes the TRM cell pool (Muschaweckh et al., 
2016). Overall, the antigen-dependence or -independence of TRM cell-development and 
maintenance seems site-specific and what is valid for the skin may differ in other organs 
(Maru et al., 2017; Thom et al., 2015; Casey et al., 2012), and can vary from epidermis to 
dermis.  
The differentiation into TRM cells in the skin and the subsequent persistence depends on 
environmental factors such as IL-15 and TGF-b (Schenkel et al., 2016; Shane et al., 2014; 
Zhang et al., 2013; Mackay et al., 2013). The TGF-b produced by several cell types in the 
skin will increase the expression of retention markers (Gebhardt et al., 2012; Travis et al., 
2014). In 2013, a seminal study provided a characterization of the in situ development of 
TRM cells in mice (Mackay et al., 2013). Mackay et al., showed that IL15-/- and TGFB-/- 
mice developed less skin CD8+CD103+ TRM cells. They could also show that the absence of 
CXCR3 on T cells led to fewer TRM cells and that the expression of IL-15 by other 
epidermal cells than T cells was instrumental to the establishment of epidermal T cells, 
indicating that the stromal microenvironment is essential to TRM cell development. In 2015, 
the same team showed that the downregulation of T-box transcription factors and EOMES 
were essential to the TRM cell formation in the epidermis, via their effect on TGF-b 
(Mackay et al., 2015). The presence of CD4+ T cells is as well crucial for CD8+ TRM cells 
to correctly express CD103 and localize within another barrier organ, the lungs (Laidlaw et 
al., 2014) but this is not as clear regarding the skin. 
1.2.4.2 Seeding 
Besides establishing in inflamed areas deprived of their cognate antigens, TRM cells can 
seed to distant skin sites at the time of the effector response, and shape a more global 
memory in other sites of the same organ (Gaide et al., 2015). The factors underlying global 
seeding are not well understood. Experimental models of viral infections suggest that 
several antigenic exposures facilitate the seeding to distant sites and that the recall response 
is weaker than at the initially infected site (Davies et al., 2017). Transposed to 
inflammatory diseases, this suggests that early-treatment strategies may limit the diffusion 
of pathogenic TRM cells. In addition to seeding at the time of acute infections, established 
skin CD4+CD103+ TRM cells can recirculate and seed to distant skin site in a model of mice 
xenotransplanted with human skin (Klicznik et al., 2019).  
1.2.4.3 Persistence 
The factors permitting the sustainability of TRM populations in the skin and other organs are 
the focus of much work. It can be arduous experimentally to differentiate the factors that 
influence the in situ development from the ones affecting the persistence. Again, most of 
what is known come from CD8+ TRM cells in mice. TRM cell-survival requires no further 
contact with their antigens (Mackay et al., 2012). A residual T-bet expression was 
necessary for the CD8+ TRM cell persistence in the skin (Mackay et al., 2015).  
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Their survival depends on exogenous lipid uptake (Pan et al., 2017). TRM cells express 
many cytokine receptors, and the absence of IL-15 and IL-7 inhibits the persistence of some 
TRM subsets in the epidermis (Adachi et al., 2015; Schenkel et al., 2016) (Figure 9).  
Keratinocytes also participate in the 
retention of TRM cells through the 
expression of the integrins avb6 and avb8 
that activate latent TGF-b (Mohammed et 
al., 2016). The factors regulating retention 
in the epidermis is likely to differ from the 
dermis. Epidermal TRM cells are suggested 
to be more sequestered in the epidermis 
than dermal ones, and less likely to 
recirculate, although this has not been 
formally demonstrated. In a model of viral 
skin infection, the depletion of cells 
accessible to the bloodstream led to the 
preferential disappearance of CD4+ TRM 
cells over epidermal CD8+ TRM cells 
(Gebhardt et al., 2011a), indicating that 
the only T cells secluded from the 
circulation were in the epidermis, and 
were CD8+.  
 
1.2.4.4 Replacement 
In mice bred isolated from common pathogens (specific pathogen-free SPF), the majority of 
epidermal T cells are dg. Upon infection, ab TRM cells do displace the epidermal gd T cells 
that were present from birth, leading to a higher proportion of ab T cells than gd T cells. 
Human fetal and neonatal T cells harbor very few epidermal T cells compared to adult skin 
(Di Nuzzo et al., 2009; Watanabe et al., 2015) and, to the best of our knowledge, their gd 
TCR assessment is lacking. Whether a displacement similar to mice occurs at birth in 
humans is not known. Fetal dermal T cells exist, both FOXP3 negative and positive, but the 
epidermal description is lacking as well as the characterization of their TCR (Schuster et al., 
2012). This shift from gd T cells to ab T cells in mice suggested than the replacement of 
older TRM cell-populations with new skin TRM cells was a general mechanism of TRM-
mediated immunity (Zaid et al., 2014). However, recent work highlighted that new TRM 
cells in the skin could implement the old TRM population, without displacing them (Park et 
al., 2018). How TRM niches jugulate their populations remains to elucidate. A hypothesis 
proposed in the literature is that in the event of tissue damage, extracellular nucleotides 
detected by TRM could trigger the death of TRM cells, and thereby give some free space for 
new cells to get installed as shown in mice liver TRM cells (Stark et al., 2018).  
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In conclusion, TRM cells are subject to much attention (Figure 10). Many questions are still 
unanswered regarding the dynamics or replacement of the cells and their survival in tissues, 
that are particularly relevant inflammatory skin diseases in TRM cells might be pathogenic. 
 
Figure 10 Popularity of TRM cells over 20 years 
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Figure 11 The skin upper layer 
Confocal microscopy was performed on an epidermal sheet from healthy donor, showing in blue the cell 
nuclei with DAPI, in red CD3 marking T cells and in green langerin marking LCs. Courtesy of Dr. Cheuk. 
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1.3 THE INFLAMED SKIN 
Inflammatory skin diseases are common and their consequences in term of quality of life 
can be dramatic for patients, with social isolation and working difficulties. The esthetic 
modifications are usually the first concern of patients, but the physical symptoms are not 
negligible: pruritus and pain can occur and be extremely difficult to live with (Balieva et al., 
2016). The financial burden for patients and health care is also increasing rapidly 
(Rosenberg and Rosenberg 2015). Schematically, an inflammatory disease is named 
autoimmune when the pathophysiology involves adaptive immunity with reactivity to self-
proteins and antigens; autoinflammatory when the innate immune system is responsible. 
Classifying a disease into one or the other category can prove challenging (Peckham et al., 
2016). The three diseases studied in this Ph.D. thesis cover different aspect of the interplay 
between resident T cells and the skin microenvironment: psoriasis is IL-17-driven and has 
a dynamic between chronic lesions, resolution and relapse that makes it a good model to 
study the role of TRM cells in relapse; contact dermatitis is an antigen-specific response to 
external factors and allows local T cell trigger with a known antigen. Vitiligo is an 
autoimmune disease with dominance of IFN-g and cytotoxic T cell activity targeting the 
melanocyte.  
1.3.1 Psoriasis 
Psoriasis affects two to four percent of the population in Sweden. The genetic background 
is inherited (Squire, 1873), and environmental triggering factors start off the symptoms 
(Yin et al., 2015; Fry et al., 2013; Farkas et al., 2010; Leung et al., 1993). Patients often 
report stress such as mourning, problems at work and childbirth as a first triggering event. 
Infections are other common triggering factors and bacterial throat infections often start 
guttate psoriasis (Leung et al., 1995). Psoriasis is also a systemic disease that can involve 
the joints, with a detectable imbalance in circulating cytokines and subsets of T cells (Bai et 
al., 2018; Arican et al., 2005; Sigmundsdóttir et al., 2001). Its association with an increased 
cardiovascular morbidity stems in this chronic inflammation (Boehncke et al., 2015). 
Clinically, psoriasis lesions are red, infiltrated, well demarcated and scaly (Boehncke and 
Schön 2015). They might itch. Several topographical subtypes are described. The most 
common is psoriasis vulgaris or plaque psoriasis that account for 90% of cases. In that form, 
the plaques are several centimeters in diameter, can cover large areas of the body and 
typically predominate on elbows, knees, and the lower back (Boehncke et al., 2015). The 
patients sampled for this Ph.D. were exclusively suffering from psoriasis vulgaris. 
Histological hallmarks of the pathology include the thickness of the epidermis 
corresponding to the keratinocyte proliferation; modification of the maturation stages of 
those keratinocytes; infiltration by immune cells such as neutrophils and infiltrating DCs 
(Kim et al., 2015).  
1.3.1.1 Skinomics: from genetics to proteomics 
Already in early medical literature, familial forms of psoriasis were described (Squire, 
1873). Antigen testing of lymphocytes could uncover that the HLA type was associated 
with psoriasis in a polygenic manner, except for patients where psoriasis outbreak was 
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induced by streptococcus (Russell et al., 1972). PSORS1 locus was later identified, 
containing HLA-C but also ten other genes, and sequencing could be performed thanks to 
technological developments. HLA-Cw6 was identified as a preeminent risk-allele for early-
onset psoriasis. Later on, thanks to the increasing size of patient cohorts, genome-wide 
association studies (GWAS) could uncover that more than 60 loci are associated to 
psoriasis, but HLA remains the strongest association (Yin et al., 2015; Liang et al., 2017).  
Beyond DNA sequence, analysis of mRNA with RT-qPCR showed upregulated transcripts 
in psoriasis skin compared to healthy skin (Elder et al., 1989). Microarrays were later 
developed with panels allowing a high throughput analysis. The non-coding genomic 
expression was explored, and several dysregulations in microRNAs were identified 
(Meisgen et al., 2012; Srivastava et al., 2017). Finally, mRNA sequencing permitted a 
global transcriptome analysis with de novo identification of transcripts of interest. As cells 
taken out of their microenvironment rapidly change characteristics, bulk analysis of skin 
tissue is preferred but raises a challenge as many cell types are present in the tissue. An 
elegant though time-consuming alternative is the use of laser capture on frozen tissue to 
select a small area with given cell types before purifying the RNA (Mitsui et al., 2012).  
Techniques allowing bioinformatical “dissection” analysis of the RNA obtained from bulk 
tissues were therefore developed concomitantly. In order to better understand the 
transcriptome output, the dysregulated transcripts can get labelled as belonging to modules 
of genes associated to given biological functions (B. Li et al., 2014). These clusters of 
genes can be defined based on the behavior of transcripts in many different types of 
samples acquired with different techniques. The pathway analysis is widely used, the most 
common being the gene ontology (GO). Another technique is the gene set enrichment 
analysis (GSEA) that runs with ranked lists instead of on an arbitrarily selected number of 
dysregulated transcripts. For instance, transcripts “set” from keratinocytes exposed to 
certain cytokine can be searched for in the transcriptome of whole tissue samples to detect 
the presence of this cytokine indirectly. Repetition of this analysis based on different 
cytokines can help estimate what was the predominant cytokine influencing a tissue at the 
time of sampling.  
Proteomics show the actual protein content of the tissue. Of note, comparison of proteomic 
and transcriptomic data in lesional psoriasis could identify substantial variations. For 
instance, in the study by Swindell et al, specific ribosomal proteins appeared strongly 
upregulated by mass spectrometry but not overexpressed at the RNA level. Opposite trends 
also existed, and only 209 differentially expressed transcripts were consistent with proteins 
changes in total (Swindell et al., 2015). The quantity of data generated by omics techniques 
is overwhelming, but it nevertheless allowed the field of psoriasis to gain knowledge on the 
physiopathology and will be reviewed in the following corresponding parts of the thesis.  
Lipidomic and metabolomic analysis of psoriasis skin may hopefully complement the 
knowledge brought by the gene/transcript/protein triad in the search for useful biomarkers 
and treatment targets in the coming years (Kang et al., 2017). 
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1.3.1.2 Immunological pathways of psoriasis 
Clinical observations added strong arguments for the implication of the immune system in 
psoriasis. For instance, a female patient developed psoriasis after receiving a bone marrow 
transplant from her brother (Gardembas-Pain et al., 1990). Before the 1970s, the interest 
was concentrated on humoral immunology, with the description of immunoglobins in the 
epidermis of psoriasis. The focus progressively shifted to T cells (Bjerke, Krogh, and Matre 
1978; Thiers 1980). Apart from their presence in skin lesions, arguments for the role of T 
cells were reinforced by psoriasis treatments. Several efficient strategies against psoriasis 
such as cyclosporine and antimetabolites have effects on T cells, although not exclusively 
(Murphy et al., 2003; Gottlieb et al., 1992). The maintenance of the plaques was shown to 
depend on the APC/T cells crosstalk, but not on E-selectin that is supposed to block the 
migration of T cells in the skin (Ellis et al., 2001; Bhushan et al., 2002). The importance of 
T cells progressively settled and psoriasis was long considered as a Th1 disease with. TNF 
and IL-17 were subsequently proven critical for psoriasis development and chronicity 
(Lowes et al., 2007), as proven by the efficiency of the TNF blockers as psoriasis 
treatments, and more recently by the blocking of IL-17 pathway, either directly with IL-17 
blockers (Langley et al., 2014; Lebwohl et al., 2015) or indirectly (anti-IL12/23 
ustekinumab). IFN-g also participates to this pathway as it programs myeloid APCs to 
induce human IL-17+ T cells through the cytokines IL-1 and IL-23 (Kryczek et al., 2008). 
The currently accepted pathophysiology of active psoriasis is summarized in Figure 12.  
Importantly, there are hints that other cell types less studied could also play a role. 
Macrophages can produce IFN-a in draining lymph nodes of psoriasis in a mice model, and 
increase T cell infiltration (Stockenhuber et al., 2018). The integration of data from GWAS 
and transcriptome could identify in what cell types the candidate genes near susceptibility 
loci were susceptible to be expressed. Surprisingly, neutrophils came out as the primary cell 
type in this analysis (Swindell et al., 2014). Although T cells are critical to psoriasis 
pathology, the constitutive or circumstantial coexistence of many immune cell types in the 
skin calls for caution in focusing all efforts on one cell type. 
1.3.1.3 The development of psoriasis – the keratinocytes 
The fact that keratinocytes from non-lesional skin differ from healthy ones suggests a 
“priming” for the development of psoriasis (Kragballe et al., 1985). Keratinocytes from 
non-lesional skin of psoriasis patients exhibit several particularities. First, a decreased 
triggering of IRF-1 and STAT1 in response to IFN-g exposure (Jackson et al., 1999). 
Second, a better integrin-dependent adhesion (Chen et al., 2001). Third, proliferation upon 
the exposure to supernatants from activated lesional T cells, which is not the case of healthy 
keratinocytes (Bata-csorgo et al., 1995). Fourth, upregulated anti-apoptotic genes and 
higher resistance to apoptosis upon UVB exposure (Bivik et al., 2017). Fifth, a modified 
gene expression analyzed by microarrays and RNA compared to healthy keratinocytes, with 
the decrease of differentiation markers (Swindell et al., 2017; Pasquali et al., 2019). Last, a 
different DNA methylation profile, including for several psoriasis candidate genes (Verma 
et al., 2018).  
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Figure 12 The current physiopathology of psoriasis  
1.3.1.4 The development of psoriasis - a role for Type 1 interferon? 
Several findings indicate that Type 1 interferons are involved in the early events of plaque 
formation. First, Type 1 interferons administrated for their antiviral properties can trigger 
psoriasis flare-ups or development (Kuzel et al., 1990; Funk et al., 1991). Second, 
plasmacytoid dendritic cells (pDCs) accumulate and produce a high quantity of Type 1 
interferon in prepsoriatic skin engrafted to mice (perilesional skin > 0,5cm from the lesion) 
and can trigger psoriasis in a Type 1 interferon-dependent manner (Nestle et al., 2005). 
Thus, Type 1 interferon could activate the myeloid DC that subsequently stimulates T cells, 
further amplifying the recruitment of more immune cells to the skin in a positive feedback 
loop. Two other findings shadowed the latter interesting discovery. The first is the 
spontaneous development of psoriasis upon engraftment of non-lesional skin onto mice, 
despite these mice’s lack of Type 1 and Type 2 interferon receptors (Boyman et al., 2004). 
The second is the inefficacy of clinical trials targeting interferons in psoriasis (Bissonnette 
et al., 2010). Nevertheless, if Type 1 interferon plays a significant role in the development 
but not in the sustainability of psoriasis, a blocking could be worth testing in a preventive 
setting and not on stable disease.  
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1.3.1.5 The development of psoriasis – T cells 
What drives the initial lesion on never previously involved skin is not known. Non-
involved skin of patients with psoriasis expresses more genes of the IL-17 pathway 
(Chiricozzi et al., 2016), and epidermal genes involved in keratinocytes differentiation such 
as SPRR2B, LCE3D and S100A7 (Gudjonsson et al., 2009). The suspicion of a subclinical 
infiltration of pro-inflammatory immune cells led several groups to test whether grafting 
of non-lesional skin on mice would trigger psoriasis development. Initially, the grafting of 
non-lesional 0,4mm thick skin onto nude mice did not trigger the development of 
histological psoriasis on the grafts (Fraki et al., 1981), although it developed markers of a 
lesion such as a higher plasminogen activator activity. Another group, proceeding to a 
similar experiment on nude mice, could witness the development of psoriasis from non-
lesional skin grafted to the mice after six weeks (Krueger et al., 1981). Two decades later, 
Boyman et al., repeated the experiment on AGR129 mice and observed the spontaneous 
development of psoriasis macroscopically and microscopically (Boyman et al., 2004). 
Additionally, the administration of high doses of the anti-CD3 antibody OKT-3 to block or 
deplete the T cells led to the blockade of psoriasis development on the grafts.  
A noticeable difference between the characteristics of the nude and the AGR129 mice 
models is the presence of NK cells in the nude mice model (Gudjonsson et al., 2007) that 
may have managed to regulate “better” the triggering of the inflammation. That no psoriasis 
was observed in the study by Fraki et al., could depend on the size of the graft, the distance 
from the lesion where the non-lesional skin was sampled, the PASI of the patients, and 
other information that did not appear in the paper. This spontaneous development might be 
driven by the enrichment of epidermal CD8+ T cells observed in non-lesional skin (Cheuk 
et al., 2014; Barbara S. Baker et al., 1984). Indeed, in non-lesional skin with few epidermal 
T cells, the blockade of T-cell migration to the epidermis through an a1b1 inhibitor was 
enough to arrest the development of psoriasis. However, if the non-lesional skin was more 
“active”, as defined by the presence of epidermal T cells in the graft, this blocking was less 
efficient (Conrad et al., 2007), emphasizing the role of epidermal T cells. These seminal 
studies clarified that skin T cells in non-lesional skin are critical for psoriasis development.  
1.3.1.6 Psoriasis as a disease of the MHC presentation? 
Psoriasis is too frequent to be aimless. Much energy and skills were deployed in looking for 
the antigen(s) of psoriasis T cells. The principal argument for an antigen-dependent process 
came from the description of HLA-C as the dominant genetic risk factor for the 
development of psoriasis (Nair et al., 2006). A defect in the regular TCR-MHC interaction 
in patients with the HLA*06:02 epitope would explain the creation of multiples 
autoreactive T cells clones in the skin. Molecular mimicry refers to the recognition of a 
harmless self-peptide by immune cell receptor due to its molecular similarity to a 
pathogenic antigen. Streptococcal throat infections trigger psoriasis guttate. The existence 
of T cell clones reacting to both the streptococcal M protein and skin keratins expressed in 
psoriasis suggested that psoriasis might arise from T cells directed against the skin 
(Valdimarsson et al., 2009; Prinz, 2004; Diluvio et al., 2014). M protein-specific T cells are 
generated after a throat infection and homes preferentially to the skin (Johnston et al., 
2004). There, the T cells recognize keratin antigens expressed either constitutionally or 
 
 43 
1.3.1.5 The development of psoriasis – T cells 
What drives the initial lesion on never previously involved skin is not known. Non-
involved skin of patients with psoriasis expresses more genes of the IL-17 pathway 
(Chiricozzi et al., 2016), and epidermal genes involved in keratinocytes differentiation such 
as SPRR2B, LCE3D and S100A7 (Gudjonsson et al., 2009). The suspicion of a subclinical 
infiltration of pro-inflammatory immune cells led several groups to test whether grafting 
of non-lesional skin on mice would trigger psoriasis development. Initially, the grafting of 
non-lesional 0,4mm thick skin onto nude mice did not trigger the development of 
histological psoriasis on the grafts (Fraki et al., 1981), although it developed markers of a 
lesion such as a higher plasminogen activator activity. Another group, proceeding to a 
similar experiment on nude mice, could witness the development of psoriasis from non-
lesional skin grafted to the mice after six weeks (Krueger et al., 1981). Two decades later, 
Boyman et al., repeated the experiment on AGR129 mice and observed the spontaneous 
development of psoriasis macroscopically and microscopically (Boyman et al., 2004). 
Additionally, the administration of high doses of the anti-CD3 antibody OKT-3 to block or 
deplete the T cells led to the blockade of psoriasis development on the grafts.  
A noticeable difference between the characteristics of the nude and the AGR129 mice 
models is the presence of NK cells in the nude mice model (Gudjonsson et al., 2007) that 
may have managed to regulate “better” the triggering of the inflammation. That no psoriasis 
was observed in the study by Fraki et al., could depend on the size of the graft, the distance 
from the lesion where the non-lesional skin was sampled, the PASI of the patients, and 
other information that did not appear in the paper. This spontaneous development might be 
driven by the enrichment of epidermal CD8+ T cells observed in non-lesional skin (Cheuk 
et al., 2014; Barbara S. Baker et al., 1984). Indeed, in non-lesional skin with few epidermal 
T cells, the blockade of T-cell migration to the epidermis through an a1b1 inhibitor was 
enough to arrest the development of psoriasis. However, if the non-lesional skin was more 
“active”, as defined by the presence of epidermal T cells in the graft, this blocking was less 
efficient (Conrad et al., 2007), emphasizing the role of epidermal T cells. These seminal 
studies clarified that skin T cells in non-lesional skin are critical for psoriasis development.  
1.3.1.6 Psoriasis as a disease of the MHC presentation? 
Psoriasis is too frequent to be aimless. Much energy and skills were deployed in looking for 
the antigen(s) of psoriasis T cells. The principal argument for an antigen-dependent process 
came from the description of HLA-C as the dominant genetic risk factor for the 
development of psoriasis (Nair et al., 2006). A defect in the regular TCR-MHC interaction 
in patients with the HLA*06:02 epitope would explain the creation of multiples 
autoreactive T cells clones in the skin. Molecular mimicry refers to the recognition of a 
harmless self-peptide by immune cell receptor due to its molecular similarity to a 
pathogenic antigen. Streptococcal throat infections trigger psoriasis guttate. The existence 
of T cell clones reacting to both the streptococcal M protein and skin keratins expressed in 
psoriasis suggested that psoriasis might arise from T cells directed against the skin 
(Valdimarsson et al., 2009; Prinz, 2004; Diluvio et al., 2014). M protein-specific T cells are 
generated after a throat infection and homes preferentially to the skin (Johnston et al., 
2004). There, the T cells recognize keratin antigens expressed either constitutionally or 
43
 44 
upon skin trauma and mistake them for a bacterial antigen. In cases with streptococcal-
associated psoriasis exacerbations, the decrease of keratin-reactive T cells correlates to the 
response to treatment and tonsillectomy could even improve patient’s quality of life 
(Thorleifsdottir et al., 2016). 
Several antigenic candidates have thereafter been described such as the antimicrobial 
peptide LL-37, skin lipids, melanocytes antigens (Lande et al., 2014; Kim et al., 2016; 
Arakawa et al., 2015; Morizane et al., 2012; Cheung et al., 2016). In most of the patients, 
however, a link with an external antigen such as bacterial infection is not clinically obvious. 
Stable psoriasis skin indeed hosts many antigen-experienced T cells, but their actual role in 
the disease development and relapse is challenging to prove as they can be attracted to the 
tissue by the local inflammation without driving the disease. Targeting these non-specific T 
cells is unlikely to improve the disease outcome. 
Psoriasis may be too frequent to be useless. The molecular mimicry that could explain the 
disease development in a category of patients may represent an evolutionary-driven 
capacity to develop strong antimicrobial responses that were useful in other human contexts. 
In order to exert such a strong selection, an infectious disease would have to be particularly 
harmful. One tempting hypothesis is that the “psoriasis genotype” has been progressively 
selected in the middle-age in response to leprosy, as these two diseases seem mutually 
exclusive, indicating that a psoriasis genotype might protect against leprosy (Wahba et al., 
1980; Bassukas et al., 2012). Following this hypothesis, anything (self or non-self) 
resembling specific Mycobacterium leprae antigens would unleash psoriasis in individuals 
genetically predisposed. 
1.3.1.7 The recurrence of psoriasis and TRM cells  
Although effective systemic treatments are available and efficient in controlling the disease, 
the relapses are frequent upon treatment discontinuation, preferentially at the site of 
previous lesions. At the molecular level, the presence of a “molecular scar” has been 
shown in healed skin under TNF blockers treatment, with transcript dysregulation in 
resolved psoriasis compared to non-lesional skin (Suárez-Fariñas et al., 2011). Notably, this 
analysis was done on whole skin biopsies and did not allow to conclude on the epidermal 
versus dermal signal. Part of the dysregulated transcripts related directly to T cells 
metabolism but many related to stromal cells, thus emphasizing that T cells are most likely 
not the only dysregulated cell type in resolved skin. An example is LCs in resolved 
psoriasis that are more prone to produce IL-23 upon TLR activation (Martini et al., 2017).  
The hypothesis of a T cell-related local cellular memory in the healed skin became one 
focus of the attention, supported by several findings. The T cell clonality exhibits 
similarities between resolved skin and lesional skin, more than with non-lesional skin 
(Vollmer et al., 2001; Matos et al., 2017). Focusing on T cells, the cell composition of the 
healed skin is indeed different: CD4+ T cells producing IL-22 and CD8+ T cells producing 
IL-17 are retained in the resolved epidermis after treatment (Cheuk et al., 2014). A causal 
role of the resident T cells in the local relapse remains to be proven. The antigens 
recognized by the retained T cells in healed psoriasis skin are unknown. Despite the 
oligoclonality of TRM cells in resolved psoriasis, the hope to find a limited number of 
antigens responsible for the disease subsists, based on the observation that resolved skins of 
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different patients shared TCR-a and TCR-b antigen receptor sequences that were absent 
from healthy samples (Matos et al., 2017). These antigens could be from the self or part of 
a microorganism. Judging by patients reported clinical information, however, finding a 
single exogenic antigen explaining psoriasis relapses in unlikely, as triggering factors has 
wide inter- and intra-individual variability. Nevertheless, TCR identifications could prove 
useful to stratify patients according to their resident clones and hopefully identify subsets of 
patients where at least one known factor triggering the relapse could be avoided. 
1.3.1.8 The skin microorganisms in psoriasis  
Reports on dysbalanced bacterial microbiota in psoriasis skin are published, with no clear 
association between disease gravity and one skin bacterium (Gao et al., 2008; Fahlén et al., 
2012; Alekseyenko et al., 2013; Tett et al., 2017). This raises the question of whether 
research should focus more on other microorganisms like viruses or fungi. The first 
argument for studying fungi is the clinical similarities existing between fungal infections 
and various forms of psoriasis (Atzori et al., 2012). This observation has baffled 
dermatologists and a “parasitic origin” of psoriasis was suggested in the past, reinforced by 
the efficacy of some antimicrobial treatments (Heaney, 1927). The second argument is that 
IL-17 is involved in the immune responses towards fungal infections (Hau et al., 2015). 
The third is that fungal products can drive psoriasis arthritis in mice, and delayed 
hypersensitivity in human (Woodfolk et al., 2000, 1996; Khmaladze et al., 2014). The 
possibility and frequency of co-occurrence of psoriasis and fungal presence in psoriasis 
have been debated in the literature, with no definite answer given (Alteras et al., 1986; 
Henseler et al., 1997). Two exciting tracks can be named here. First, microbial coexistence 
between bacteria and fungi species are different in psoriasis and in healthy skin (Stehlikova 
et al., 2019). Inter-species interactions could create additional antigens susceptible to act on 
T cells. Second, the high frequency and diversity of malassezia in psoriasis skin (Takemoto 
et al., 2014). In experimental settings, circulating T cells of psoriasis patients react to 
Malassezia furfur with increased production of IFN-γ (Kanda et al., 2002). Malassezia is 
more commonly found in the scalp of patients with psoriasis than the controls 
(Rudramurthy et al., 2014). This field might bring answers regarding frequent antigenic 
exposure of psoriasis skin in the coming years, but technical challenges remain as many 
detected microbial sequences in the skin remain difficult to link to known microorganisms.  
1.3.1.9 Treatments 
Psoriasis severity is very variable, and the majority of patients with a relatively limited 
disease will not need systemic oral treatments. Sea bath and sun is known to improve 
psoriasis since ancient times, and it is not altogether impossible that the inheritable leprosy 
“as white as snow” from Bible’s Neeman that improved after six baths in the Jordan was 
psoriasis (Squire, 1873; Vora, 2015). In UV therapy, both UVA and UVB can be used. 
Narrow-band UVB is the modern treatment of choice, and the current regiment in Sweden 
involves UVB exposure (313nm) three times a week, for a total of 25 to 30 times. This 
treatment can be repeated once a year during several years without increasing the risk of 
skin cancer. UVB and UVA decrease the density of immune cell in the skin, both dendritic 
cell and T cells, and even have systemic effects (Sigmundsdottir et al., 2005; Pearse et al., 
 
 45 
different patients shared TCR-a and TCR-b antigen receptor sequences that were absent 
from healthy samples (Matos et al., 2017). These antigens could be from the self or part of 
a microorganism. Judging by patients reported clinical information, however, finding a 
single exogenic antigen explaining psoriasis relapses in unlikely, as triggering factors has 
wide inter- and intra-individual variability. Nevertheless, TCR identifications could prove 
useful to stratify patients according to their resident clones and hopefully identify subsets of 
patients where at least one known factor triggering the relapse could be avoided. 
1.3.1.8 The skin microorganisms in psoriasis  
Reports on dysbalanced bacterial microbiota in psoriasis skin are published, with no clear 
association between disease gravity and one skin bacterium (Gao et al., 2008; Fahlén et al., 
2012; Alekseyenko et al., 2013; Tett et al., 2017). This raises the question of whether 
research should focus more on other microorganisms like viruses or fungi. The first 
argument for studying fungi is the clinical similarities existing between fungal infections 
and various forms of psoriasis (Atzori et al., 2012). This observation has baffled 
dermatologists and a “parasitic origin” of psoriasis was suggested in the past, reinforced by 
the efficacy of some antimicrobial treatments (Heaney, 1927). The second argument is that 
IL-17 is involved in the immune responses towards fungal infections (Hau et al., 2015). 
The third is that fungal products can drive psoriasis arthritis in mice, and delayed 
hypersensitivity in human (Woodfolk et al., 2000, 1996; Khmaladze et al., 2014). The 
possibility and frequency of co-occurrence of psoriasis and fungal presence in psoriasis 
have been debated in the literature, with no definite answer given (Alteras et al., 1986; 
Henseler et al., 1997). Two exciting tracks can be named here. First, microbial coexistence 
between bacteria and fungi species are different in psoriasis and in healthy skin (Stehlikova 
et al., 2019). Inter-species interactions could create additional antigens susceptible to act on 
T cells. Second, the high frequency and diversity of malassezia in psoriasis skin (Takemoto 
et al., 2014). In experimental settings, circulating T cells of psoriasis patients react to 
Malassezia furfur with increased production of IFN-γ (Kanda et al., 2002). Malassezia is 
more commonly found in the scalp of patients with psoriasis than the controls 
(Rudramurthy et al., 2014). This field might bring answers regarding frequent antigenic 
exposure of psoriasis skin in the coming years, but technical challenges remain as many 
detected microbial sequences in the skin remain difficult to link to known microorganisms.  
1.3.1.9 Treatments 
Psoriasis severity is very variable, and the majority of patients with a relatively limited 
disease will not need systemic oral treatments. Sea bath and sun is known to improve 
psoriasis since ancient times, and it is not altogether impossible that the inheritable leprosy 
“as white as snow” from Bible’s Neeman that improved after six baths in the Jordan was 
psoriasis (Squire, 1873; Vora, 2015). In UV therapy, both UVA and UVB can be used. 
Narrow-band UVB is the modern treatment of choice, and the current regiment in Sweden 
involves UVB exposure (313nm) three times a week, for a total of 25 to 30 times. This 
treatment can be repeated once a year during several years without increasing the risk of 
skin cancer. UVB and UVA decrease the density of immune cell in the skin, both dendritic 
cell and T cells, and even have systemic effects (Sigmundsdottir et al., 2005; Pearse et al., 
45
 46 
1987; Ozawa et al., 1999). UVA penetrates deeper into the skin than UVB (Meinhardt et al., 
2008) and can cause more DNA damage. The use of PUVA therapy is limited since it 
promotes skin malignancies (Archier et al., 2012; Lindelöf et al., 1992). It reaches deeply-
rooted immune cells in the epidermis, and modify the cell populations in the dermis. 
Modification of epidermal composition of T cells in the skin under PUVA treatment has 
been shown to precede the clinical improvement, but not the dermal composition or the 
APC composition, underlining again the importance of the epidermal compartment in 
psoriasis (Baker et al., 1985). UVA is usually associated with a photosensitizer extracted 
from the Psoralea plant. Skin is exposed to psoralen either orally or locally with bath-
PUVA.  
The treatment of psoriasis builds on local treatments such as steroids, vitamin D, or tar. 
Several therapeutic revolutions occurred in the past decades. First, non-targeted systemic 
therapies appeared such as retinoids, cyclosporine and methotrexate, which remains the 
first line of systemic therapy. Therapies targeting cytokines were introduced more recently, 
following the lead of rheumatoid arthritis. TNF blockers, anti-IL12/23, anti-IL-17 are the 
main categories (Boehncke et al., 2015; Hueber et al., 2010). The clinical response to 
biologics has recently been linked to single nucleotide polymorphisms (SNP), with patients 
expressing variants related to high levels of IFN-g to be more likely to respond to anti-
IL12/23 (Loft et al., 2018).  
1.3.2 Allergic Contact Dermatitis 
1.3.2.1 Clinics, diagnosis and genetics 
Allergic contact dermatitis (ACD) is the clinical manifestation of contact allergy upon re-
exposure to the causative hapten. Contact allergy is a very common pathological reaction 
pattern with an estimated prevalence of 20% in Europe (Alinaghi et al., 2019). It has 
significant occupational consequences as the allergy often is the result of a work-related 
exposure. The chronic inflammation is directed against a hapten (Girolomoni et al., 2004) 
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clinical presentation might differ and make the diagnosis challenging. Upon diagnostic 
patch testing, the skin is exposed to a panel of chemicals in a controlled way, usually as 
occlusion patch tests on the back of the patients (Mowad et al., 2016). The reading of the 
test is preferably done twice: first after two days when the exposure ceases and then at day 
five to seven (Figure 13). A positive test consists of an eczematous lesion confined to the 
exposure site on the back but in some cases even previously affected skin sites flare up. A 
biopsy is usually not necessary. When performed, it shows spongiosis, intraepidermal 
vesicles, moderate epidermal and perivascular lymphocytic infiltrate and papillary dermal 
edema. Various treatment strategies are possible, but the only cure is allergen avoidance, as 
local persistence of the antigen in the skin leads to an extended duration of disease (Rashid 
et al., 2016; Kaidbey et al., 1984). Avoidance is challenging for the patients since the 
source of the exposure is not seldomly hidden for the patient and can be linked to his/her 
occupation. 
Genetic predisposition has been described in rodent equivalent of ACD named cutaneous 
hypersensitivity (CHS). Breeders observed that different strains had a variable probability 
of developing CHS despite using similar protocols (Chase et al., 1941; Turk, 1968). In 
humans, first degree relatives of patients with nickel ACD have a 2,83 RR to develop the 
disease (Fleming et al., 1999). GWAS identified loci associated with nickel ACD (Kim et 
al., 2013). Variation in TNF, its promoter region, and deletion of late cornified envelope 
antigens (LCE) 3B and 3C among others have been associated to ACD (Ertam et al., 2009; 
Dittmar et al., 2017; Molin et al., 2011; Schnuch et al., 2011). Interestingly, neither HLA 
nor filaggrin mutations are major genetic factors associated to the development of ACD 
(Landeck et al., 2014; Silvennoinen-Kassinen et al., 1979), but it associates to an earlier 
onset (Carlsen, et al., 2010). Patients suffering from ACD have an insufficient generation of 
bulk ceramides that, together with a facilitating local factor such as an occupation with 
frequently humid skin, could facilitate the development of ACD (Kim et al., 2017; Jakasa et 
al., 2018).  
1.3.2.2 Sensitization and elicitation 
ACD is a model of Type IV allergy. A T cell-dependent skin allergy is named Type IV in 
opposition to the three other types in which antibodies and mast cells are responsible for the 
symptoms (Warrington et al., 2018). It refers to a T cell-dependent mechanism where the 
first contact with a substance will lead to sensitization with the development of memory T 
cells. This first step can be totally. The next exposure – or challenge will trigger a robust 
immune response and symptoms. Several categories can be differentiated among Type IV 
allergies. In each case the antigen activates T cells but the effect in the tissue differs. In IVa, 
the production of IFN-g will lead to macrophage activation, as in tuberculin reaction or in 
ACD. In IVb, IL-4 and IL-5 will be released from Th2 cells, leading to the recruitment of 
eosinophils, as in drug reaction with eosinophils and systemic symptoms (DRESS) 
syndrome. In IVc, cytotoxic T cells will be responsible for direct cytotoxicity, as in toxic 
epidermal necrosis (TEN) and fixed drug eruption (FDE) (Phillips et al., 2018). 
The sensitization to an allergen in ACD starts with the penetration of a hapten in the skin. 
A molecule can in some cases become a hapten by oxydation prior to the entrance in the 
skin (pre-hapten), after metabolisation in the skin (pro-hapten), or by UV exposure as in 
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photoallergic contact dermatitis (Kerr et al., 2010; Kaplan et al., 2012). Haptens are small 
molecules that can easily penetrate in the skin contrarily to protein antigens (Kabashima et 
al., 2018). The presence of the hapten in the skin will trigger the innate immune system 
with effects on keratinocytes and mast cells via TLR activation (Kaplan et al., 2012) and 
then be internalized by an APC. The APC will get activated and leave the skin to present its 
content in a draining lymph node. Both LCs and dermal DCs can fulfil this function 
(Streilein, 1989; Bennett et al., 2007; Fukunaga et al., 1990) although it seems LCs are 
more prone to trigger regulatory responses. In the presence of the right co-activation signals 
in the lymph nodes, naïve T cells will become activated and move back to the site of 
inflammation (Saint-Mezard et al., 2003). It is noticeable that CD8+ T cells are the quickest 
to be on site and the most responsible for the effector events in ACD (Vocanson et al., 2006; 
Hennino et al., 2011).  
After resolution of the infection, the next encounter of the hapten will lead again to the 
presentation by APCs to memory T cells. These T cells are either present in the skin or 
recruited, leading to the elicitation of ACD. The accumulation of LCs is a classical sign of 
the ACD pathology in the skin, stressing their participation in the disease (Rosa et al., 
2016). Since APCs, T cells, and the hapten are present in the same location during 
elicitation, there are several ways for the hapten to get involved in the MHC-TCR 
relationship (Moulon et al., 1995). The hapten can bind to a protein before entering an APC, 
and stay attached until MHC presentation, bind to the peptide after it was loaded on an 
MHC, or bind to the TCR directly and get in contact in the peptide there (Figure 14). 
 
Figure 14 Hapten presentation in ACD 
1.3.2.3 Disrupting the basement membrane 
Contact dermatitis exhibits histological findings similar to atopic dermatitis where T cells 
transmigrate from the vessels to the dermis and will relocate to the epidermis. Atopic 
dermatitis is associated to a lower expression of collagen IV at the basement membrane that 
is correlated to the presence of IL-13 (Kim et al., 2018; Shin et al., 2015). Decreased 
collagen IV is believed to ease the penetration of immune cells into the epidermis. 
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Metalloproteases (MMPs) are enzymes that can degrade different collagens and blocking 
MMPs can impair the T cell migration through vessels’ basement membrane through the 
action on collagen IV (Gschwandtner et al., 2008). Different cell types can produce MMPs 
(Swindell et al., 2013), including keratinocytes (Tewari et al., 2014; Manetti et al., 2012). 
MMP-12 can degrade both collagen IV and dermal collagens and its transcript can be 
induced in keratinocytes upon exposure to cytokines (Swindell et al., 2013 2012). The 
proteolytic functions of MMPs can also target chemokines and cytokines (McQuibban et al., 
2000) with, for instance, MMP-12 truncating IFN-g on its receptor binding sequence 
(Dufour et al., 2018). Metalloproteinases can thus superimpose several tissue-relevant 
functions. Factors arising directly from T cells can also help attack the basement membrane. 
For instance, Granzyme B produced by CD8+ T cells can increase the transmigration of T 
cells and remodel the extracellular matrix (Prakash et al., 2014).  
1.3.2.4 TRM cells in T-cell mediated allergies 
An elegant human example of TRM cells in Type IV skin allergy is the almost exclusively 
epidermal disease fixed drug eruption (FDE), where the sensitization to a medication will 
trigger an accumulation of medication-specific T cells in given skin areas. TRM cells 
migrate to the skin (Mizukawa et al., 2002), and then persist at the dermal-epidermal 
junction in healed lesions. These cells lie in the epidermis and are for 90% CD8+ 
(Mizukawa et al., 2008). The areas involved are usually limited and the lesion can be 
unique, first erythematous and later hyperpigmented. Exceptions to that are the 
disseminated FDE and more severe bullous forms. One characteristic of FDE is the lifelong 
persistence of the reactivation of the lesion if the substance is administrated again. Upon 
challenge, they produce high level of IFN-g and granzymes (Teraki et al., 2003). CD4+ cells 
are also present in smaller number and are composed primarily of Tregs in the lesion 
(Mizukawa et al., 2008). Upon rechallenge, the same sites will develop the lesions, but it is 
not unusual that subsequent challenges will involve progressively larger skin zones, but 
seldom new areas. It is puzzling to consider that FDE is clinically little susceptible to the 
seeding phenomena of TRM cells, whereas ACD is. Indeed, to diagnose FDE, a patch-test 
has to be positive on the healed skin and negative on the non-lesional skin, whereas the 
patch-test can be applied to any skin site for ACD and still trigger inflammation within a 
couple of days, reflecting the presence of skin memory T cells. The specific homing of 
CD8+ TRM cells in the epidermal compartment in FDE versus a more shared epidermal and 
dermal residency of both CD4+ and CD8+ TRM cells in ACD could be an explanation and 
underlines the relevance of learning from both epidermal and dermal compartments in 
human TRM cell biology. Very interestingly, cases of successful desensitization are 
described where the repetitive and gradually increasing exposure reinforced the CD4+ T 
cell-population in the epidermis as well as the presence of CD25+ T cells, indicating the 
presence of Tregs (Teraki et al., 2004). Patients were then able to re-take the medication. 
Thus, control of the disease could be achieved by artificially modifying the skin T cells 
composition poising it toward an improved regulatory balance. The observation that 
Japanese patients got FDE on the site of recent HSV infections led to a hypothesis that 
HSV-specific cross-reactive skin T cells would react to drug-modified keratinocytes 
(Shiohara et al., 2012). This form of drug-induced molecular mimicry would trigger FDE. 
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In TEN, the skin reaction is stronger, with separation of epidermis and dermis and mucosal 
involvement leading to intense pain and high risks of infection and death. Some severe 
cases of FDE can mimic TEN (Mitre et al., 2017). They differ in their pathology by a 
higher infiltrate of CD4+ dermal T cells, including FOXP3+ ones and less intraepidermal 
cytotoxic T cells (Cho et al., 2014). The causal factor is most often a drug, but viral and 
bacterial infections can be involved as well (Merot and Saurat 1985). CD8+ T cells are also 
present in the lesions (Miyauchi et al., 1992). Skin allergy could be triggered in 
immunocompromised mice upon injection of PBMCs from an allergic human and graft of 
its skin onto the mice. This effect disappeared with the depletion of CD8+ T cells – 
indicating the essential role of this subset in the disease (Saito et al., 2013). TRM cells have 
so far not been characterized in TEN.  
In ACD, the exposure to the hapten takes place in the skin usually both at sensitization and 
at elicitation. The first one is considered as a prerequisite, although elicitation (challenge) 
can occur after systemic administration as well. The immune response varies depending on 
the hapten. Transcriptomic analysis showed that only a few genes are commonly 
dysregulated by common allergens such as nickel, rubber and fragrance altogether, but the 
type of response is common, mainly Th1 and Th2 but also Th17/Th22 (Dhingra et al., 
2014). The kinetics deciphering of the immune response upon skin-challenge with haptens 
showed that gene expression at day 3 involved all major T cell subsets, and was more 
regulatory at day 14 (Gulati et al., 2014). The skin persistence of allergen-primed T cells 
after challenge was suspected long before their identification in guinea pigs (Rustemeyer et 
al., 2002; Scheper et al., 1983) and more recently, the generation of TRM cells in the skin 
was demonstrated both in CHS and in ACD. The hapten triggers a quicker inflammation in 
previously exposed skin, illustrating the expansion of antigen-specific TRM cells (Gaide et 
al., 2015). In term of function, TRM cells in CHS can quickly produce IFN-g and very little 
IL-17 upon challenge with PMA/ionomycin (Schmidt et al., 2016). How long these cells 
remain present in the human skin after a challenge is still unknown, at least for several 
months in mice according to a recent study that also emphasized the pathogenic role or 
epidermal allergen-specific resident cells in this disease as CD8+ TRM cells were 10 times 
more frequent in the epidermis than in the dermis. Additionally, CD8+ TRM cells could 
trigger a flare by themselves without the participation of blood T cells and their 
elimination abrogated the allergen-induced flares (Gamradt et al., 2019). 
1.3.2.5 Methylisothiazolinone 
Methylisothiazolinone (MI) is a potent skin sensitizer used as a preservative in many 
cosmetic, household, and industrial products such as paints. In 2005, it was introduced on 
the market in 25 times higher concentration than its previous use, as a mixture of 
Methylchloroisothiaozolinone (MCI) and Methylisothiazolinone. Soon an epidemic of 
ACD was observed due the presence of MI in personal care products and water-based 
paints (Venables et al., 2016). The incidence peak seems to have passed, probably due to 
regulation of the EU and the self-regulation of the cosmetic industries who have started to 
replace MI by other conservatives (Uter et al., 2019).  
As mentioned above, MI and MCI have long been used together as a preservation mixture 
and many patients who sensitized primarily to the more potent hapten MCI developed ACD 
to products containing MI due to cross-reactivity (Stingeni et al., 2018). MI binds to 
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epidermal cysteine thiols residues in order to become antigenic in the reconstituted human 
epidermis (Debeuckelaere et al., 2016). It leads to T cell proliferation in ACD patients and 
creates a Th1 and Th2 reaction in PBMCs (Masjedi et al., 2003; Popple et al., 2016).  
1.3.3 Vitiligo 
Vitiligo is an autoimmune skin disease. Several genetic loci have been identified and many 
are shared with rheumatoid arthritis, type-1 diabetes and celiac disease (Jin et al., 2016). 
Vitiligo is the whitening of the skin by the absence of melanin produced by the melanocytes 
(Figure 15). The most common body parts involved are the hands, the knees, but any part of 
the skin can be involved. Skin areas exposed to frictions and trauma are more prone to 
develop vitiligo. 
1.3.3.1 Treatment and physiopathology 
The disease pathophysiology is not straightforward and involves oxidative stress, 
autoantibodies and cytotoxic T cells. Melanocytes are absent of the inter-follicular 
epidermis in vitiligo lesions but remain in hair follicles, and start to proliferate during 
treatment (Cui et al., 1991; Ortonne et al., 1980). Melanocyte-derived auto-antigens have 
been identified, such as Melan-A and gp100 proteins (Palermo et al., 2005; Oyarbide-
Valencia et al., 2006). Infiltration of CD8+ T cells capable of killing melanocytes is present 
in perilesional of patients with vitiligo (Wu et al., 2013). The causal role of T cells in 
vitiligo is supported by the occurrence of vitiligo in 12% of the melanoma patients treated 
with the anti-CTLA4 Ipilimumab, and the development of 
vitiligo during immunotherapy is proposed as a good 
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limited efficacy. Surgical interventions are sometimes 
proposed in case of stable vitiligo, such as the 
transplantation mixtures of epidermal and dermal cells from 
non-lesional skin onto involved areas (Thakur et al., 2019). 
Systemic pulses of steroids can also help to stop disease 
progress (Tovar-Garza et al., 2019).  
1.3.3.2 TRM cells in Vitiligo 
Vitiligo has clinically a tendency to come back in selected 
areas of the body, suggesting the implication of TRM cells in 
the pathogenesis. Several studies investigated the 
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Perilesional skin of vitiligo patients exhibited an 
accumulation of cytotoxic TRM cells and high expression of 
CXCR3 (Boniface et al., 2018). At the tissue level, 
keratinocytes responses to IFN-g were necessary to the 
induction of vitiligo in a mouse model in which the 
inhibition of IFN-g production by T cells was later shown to induce re-pigmentation 
(Richmond et al., 2018). These findings, together with ours (Cheuk et al., 2017), 
 
Figure 15 Vitiligo clinical 
presentation 
 
 51 
epidermal cysteine thiols residues in order to become antigenic in the reconstituted human 
epidermis (Debeuckelaere et al., 2016). It leads to T cell proliferation in ACD patients and 
creates a Th1 and Th2 reaction in PBMCs (Masjedi et al., 2003; Popple et al., 2016).  
1.3.3 Vitiligo 
Vitiligo is an autoimmune skin disease. Several genetic loci have been identified and many 
are shared with rheumatoid arthritis, type-1 diabetes and celiac disease (Jin et al., 2016). 
Vitiligo is the whitening of the skin by the absence of melanin produced by the melanocytes 
(Figure 15). The most common body parts involved are the hands, the knees, but any part of 
the skin can be involved. Skin areas exposed to frictions and trauma are more prone to 
develop vitiligo. 
1.3.3.1 Treatment and physiopathology 
The disease pathophysiology is not straightforward and involves oxidative stress, 
autoantibodies and cytotoxic T cells. Melanocytes are absent of the inter-follicular 
epidermis in vitiligo lesions but remain in hair follicles, and start to proliferate during 
treatment (Cui et al., 1991; Ortonne et al., 1980). Melanocyte-derived auto-antigens have 
been identified, such as Melan-A and gp100 proteins (Palermo et al., 2005; Oyarbide-
Valencia et al., 2006). Infiltration of CD8+ T cells capable of killing melanocytes is present 
in perilesional of patients with vitiligo (Wu et al., 2013). The causal role of T cells in 
vitiligo is supported by the occurrence of vitiligo in 12% of the melanoma patients treated 
with the anti-CTLA4 Ipilimumab, and the development of 
vitiligo during immunotherapy is proposed as a good 
prognosis factor (Hodi et al., 2010; Hua et al., 2015). 
Treatments include topical steroids and UV therapy with 
limited efficacy. Surgical interventions are sometimes 
proposed in case of stable vitiligo, such as the 
transplantation mixtures of epidermal and dermal cells from 
non-lesional skin onto involved areas (Thakur et al., 2019). 
Systemic pulses of steroids can also help to stop disease 
progress (Tovar-Garza et al., 2019).  
1.3.3.2 TRM cells in Vitiligo 
Vitiligo has clinically a tendency to come back in selected 
areas of the body, suggesting the implication of TRM cells in 
the pathogenesis. Several studies investigated the 
mechanistic basis of TRM cells implication in vitiligo. 
Perilesional skin of vitiligo patients exhibited an 
accumulation of cytotoxic TRM cells and high expression of 
CXCR3 (Boniface et al., 2018). At the tissue level, 
keratinocytes responses to IFN-g were necessary to the 
induction of vitiligo in a mouse model in which the 
inhibition of IFN-g production by T cells was later shown to induce re-pigmentation 
(Richmond et al., 2018). These findings, together with ours (Cheuk et al., 2017), 
 
Figure 15 Vitiligo clinical 
presentation 
51
 52 
collectively established TRM cells as a likely mechanism of vitiligo development. The 
dermal localization of the infiltrate, however, might complicate topical treatments aiming at 
T cell population remodeling, as they will be less easily reached than in ACD or psoriasis. 
Current therapeutic perspectives include tofacitinib, a pan-JAK inhibitor that suppresses IL-
15 signaling that has been reported effective against vitiligo (Craiglow et al., 2015). 
Additionally, the blocking of the receptor subunit that allows IL-15 binding to its receptor 
efficient on mice vitiligo (Richmond et al., 2018).  
In conclusion, the skin is a complex organ that is particularly suitable for TRM study by its 
relatively easy sampling with minimal scarring and risks for patients. Additionally, if a 
remodeling of epidermal TRM cells is achievable through external treatments, it could prove 
very useful in skin inflammatory diseases. With the current techniques used in immunology, 
improved knowledge about human biology can be reached by studying the skin, and will 
hopefully open new perspectives of treatments for other inflammatory diseases. 
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2 AIM AND RESEARCH QUESTIONS 
The Ph.D. thesis aimed to increase our understanding of how TRM cells impact on the skin 
microenvironment during the onset and relapse of common inflammatory skin diseases. 
This thesis is divided in four research questions: 
Question 1: In human skin, are functionally distinct TRM cell subsets altered in 
inflammatory skin diseases?  
Question 2: In skin that has never been affected by psoriasis, do TRM cells differ in 
composition and functionality?  
Question 3: Are TRM cells from resolved psoriasis skin capable of initiating clinically 
relevant tissue responses?  
Question 4: How do allergen-specific TRM cells provoke disease-driving tissue responses in 
resolved allergic contact dermatitis? 
 
 
Figure 16 Research questions 
 
 53 
2 AIM AND RESEARCH QUESTIONS 
The Ph.D. thesis aimed to increase our understanding of how TRM cells impact on the skin 
microenvironment during the onset and relapse of common inflammatory skin diseases. 
This thesis is divided in four research questions: 
Question 1: In human skin, are functionally distinct TRM cell subsets altered in 
inflammatory skin diseases?  
Question 2: In skin that has never been affected by psoriasis, do TRM cells differ in 
composition and functionality?  
Question 3: Are TRM cells from resolved psoriasis skin capable of initiating clinically 
relevant tissue responses?  
Question 4: How do allergen-specific TRM cells provoke disease-driving tissue responses in 
resolved allergic contact dermatitis? 
 
 
Figure 16 Research questions 
53
 54 
 
 
  
 
 
 
54 
 
 
  
 
 
54
  55 
3 METHODS 
3.1 SKIN  
Biopsies (PAPERS I, II, III, IV) 
Skin from healthy patients lacking history or symptoms of inflammatory skin diseases was 
obtained through the plastic surgery department. Skin from patients with the following 
conditions was sampled: 1/ Vitiligo (PAPER I) both lesional and non-lesional; 2/ Allergic 
Contact dermatitis (PAPER IV), lesional and non-lesional, at diagnosis and after two 
months or after two years after the resolution of symptoms; 3/ Psoriasis, both lesional, 
never-lesional, resolved after UVA, UVB, biologics treatments (PAPER II, III). Skin 
biopsies were collected and processed (within 4 hours) or immediately cryopreserved at -
80°C. Untreated psoriasis skin was collected at least one centimeter inside the edge of the 
lesion. Resolved lesions in psoriasis were identified with help of photographs, 
hyperpigmentation or reliable patient history. All tissue samples were collected according 
to the Declaration of Helsinki Principles and approved by the regional ethical committee of 
Stockholm, reference no: 2012/50-31/2, 2015/0041-32, 2013/976-31/4, 2017/1774-32. 
Signed consent forms were collected. 
Confocal microscopy (PAPER I, II, III) 
Cryopreserved skin biopsies were sectioned (10 µm) at -20°C, fixed and permeabilized 
using Transcription Factor Staining Buffer Set (00-5523-00, eBioscience) and incubated 
with antibodies overnight at 4°C. Amplification using streptavidin-conjugated antibodies 
(anti-mouse, Vector) in PAPER III was followed by fluorochrome labelling. Images were 
acquired in a laser scanning confocal microscopy and analyzed in Fiji. Antibodies used 
were: MMP-12 (ab137444 from abcam and 703D10 from movus bio), Collagen IV (clone 
COL-94, Abcam), CD8 (AB4055, AbCAM), CD3 (clone CD3-12, Abcam), MelanA (clone 
EP1422Y, Abcam), keratin 5/6 (cloneD516, DAKO), CD49a (clone 550594, BD 
Bioscience). 
Stimulation of skin biopsies 
In PAPER II, III, IV, full-thickness skin biopsies were incubated in Dulbecco’s Modified 
Eagle Medium (DMEM, Gibco) supplemented with fetal bovine serum (FBS Hyclone) 10% 
and PEST (penicillin 100 units/ml and streptomycin 100 mg/ml; Gibco by LifeTech, 
Waltham, MA) in the presence of different products. To simulate an antigenic ligation, 
αCD3 antibody OKT-3 (CD3ε) 1µg/mL was compared to a control IgG2a control 1µg/mL 
(both both Biolegend, Ultra LEAF). Exposure to cytokines was also performed to study 
tissue responses: rhIL-17A 100ng/mL, rhIFN-γ 100ng/mL (all from R&D Systems, 
Minneapolis, Minn) for 16 hours. In PAPER III, Mannans from Saccharomyces cerevisiae 
or Malassezia furfur, Heat killed Candida albicans (in PAPER II) were used to mimic 
contact with common fungi. The peptides P5 (YIIDTGIDID) and P24 (LSGTSMASPH) 
from Trichophyton rubrum were custom-made and ordered from Sigma Aldrich. 
Methylisothiazolinone (100ppm) (Sigma Aldrich 725765-5g) was used in PAPER IV to 
perform an antigen-specific stimulation of memoy T cells. For the various stimulations, 
skin explants were incubated for 16-48 hours at 37°C. When collected, supernatants were 
immediately cryopreserved at -80°C. 
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ELISA and Collagenase assay 
Thawed supernatants were analysed using ProcartaPlex™ (eBioscience) in PAPER III; 
ELISA and the CCL-20 ELISA (Quantikine ELISA Kit Human CCL-20/MIP-3 alpha, 
R&D systems) in PAPER II according to the manufacturer’s protocol and read using Bio-
Rad Bio-Plex 200 System (Bio-Rad Laboratories). Cut-off for detection was set at 10pg/mL. 
In PAPER IV, the properties of rhMMP-12 and rhMMP-1 (RnD systems) were tested at 2 
to 2000ng/mL, on collagen IV and collagen I using the EnzChek® Gelatinase/Collagenase 
Assay Kit (Thermofisher) together with DQ™ collagen type I and DQ™ collagen type IV 
from Thermofisher. After 2-7 days of incubation, the plate was read using a fluorescence 
reader. 
3.2 RNA 
Purification of RNA from biopsies (PAPER II, III, IV) and q-PCR 
After incubation at 37°C, epidermis and dermis were separated after incubation in 5 U/ml 
Dispase in PBS overnight at 4°C, and cryopreserved in Qiazol at -80°C until tissue 
homogenization using a TissueLyser (Qiagen) for 4 min at 50Hz. Total mRNA was purified 
with miRNeasy kit (Qiagen) according to manufacturer’s protocol. RNA quality and 
quantity were checked using either Nanodrop or Bioanalyser RNA Nano Kit (Agilent). 
RNA was conserved in RNase free water at -80°C until analysis. RNA was converted to 
cDNA using the HighCapacity cDNA Reverse Transcription Kits (Applied Biosystems). 
Reverse transcription Quantitative PCR (RT-qPCR) was performed using TaqMan PreAmp 
Master Mix Kit (Applied Bioscience) and the TaqMan Gene Expression Master Mix 
(Applied Bioscience) following the manufacturers’ protocols. Gene expression was 
normalized to the house-keeping gene b2-microglobulin (B2M).  
RNA sequencing (PAPER I, III, IV) 
mRNA was first enriched with oligo(dT) beads, then fragmented randomly. cDNA is 
synthetized using random hexamers and reverse transcriptase. The synthesis buffer 
containing dNTPs (illumina) is added together with RNase H and E. coli polymerase I to 
generate the second strand. The final library is ready after A-tailing, adapter ligation, PCR 
enrichment. The library concentration is quantified using Qubit 2.0 fluoromer (life 
technologies), then diluted to 1ng/uL before checking the insert size on Agilent 2100 and 
quantifying by RT-qPCR. For all samples, the sequencing was performed on HiSeqTN 
2000 (Illumina) and the reference genome for alignment was hg19. In PAPER I and III, 
the library construction was done using SMARTSeq v4 Ultra Low Input RNA Kit 
(ClonTech) and sequenced on Illumina HiSeqTM 2000, at Beijing Genomic Institute, (BGI, 
Hong Kong). The analysis was performed by BGI using the pipeline in Figure 17. 
Alignment was performed with Bowtie and data are available at 
www.ncbi.nlm.nih.gov/geo/query/acc.cgi, GSE103489 for PAPER III, GSE83637 for 
PAPER I. In PAPER IV, RNA was sequenced by Novogene. Genevia Technologies 
(Tampere, Finland) performed the analysis using a similar pipeline. TopHat2 (also using 
Bowtie) was used for the alignment. Aligned reads per gene were counted with htseq-
counts using the genome fasta and annotation gtf files as references. After counting, 
normalized gene expression estimates were computed using TPM (transcripts per kilobases 
per million reads) method which first normalizes for gene length, and then for sequencing 
depth. Data are not yet deposited. 
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Nanostring Technologies (PAPER II, III, IV) 
Nanostring is a quantitative method counting RNA copies and was performed according to 
manufacturer’s protocol (NanoString Technologies, Inc. Custom CodeSet). One custom 
panel of 119 genes was used for PAPER II and III and a second larger panel of 200 
transcripts was used for PAPER IV, including the same 5 house-keeping genes (G6PD, 
GUSB, HPRT1, SF3A3, ZC3H14) in both panels. NOL7 was not used as a HKG as it 
showed too much variability in between samples. RNA counts were generated in nSolver 
software (NanoString Technologies, Inc.). Analysis were performed with JMP 12 and with 
the company Genevia Technologies (Tampere, Finland) for the generation of differentially 
expressed genes and time-series analysis. 
 
Figure 17 mRNA sequencing and analysis pipeline 
Hg = human genome, QC = quality control, TPM =Transcripts Per Kilobase Million, FKPM = Fragment Per 
Kilobase Million, DEA = differential expression analysis, GO = gene ontology, GSEA = gene-set enrichment 
analysis.  
3.3 CELLS 
Keratinocytes culture 
Punch biopsies were placed in dispase as described above. The following day, the 
epidermis was separated from the dermis and treated with 0.05% Trypsin/EDTA (Gibco) 
for 30 minutes at 37°C. DMEM and FBS were used to interrupt the reaction. The epidermal 
cell suspension was cultured in a flask coated with collagen I (Gibco) in EpiLife medium 
(Gibco) supplemented with human keratinocyte growth supplement (Gibco), 100 U/ml 
PEST and Fungizone (Gibco). Keratinocytes were then frozen for later use. Ten thousand 
thawed keratinocytes (passage 3) were plated in 48 well plates, and exposed to 
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recombinant(r) human cytokines in PAPER III during 16 hrs after they reached a 100% 
confluence: rhIL-17A 5 ng/mL, rhIFN-γ 5 ng/mL, rhIL-22 (5 ng/mL), rhTNF (5 ng/mL), 
rhIFN-a (5 U/mL) (all from R&D Systems, Minneapolis, Minn) for 16 hours. 
Preparation of skin cell suspension from biopsies 
Patients biopsies (4mm) or healthy skin biopsies (6mm) were incubated in 5U Dispase (Life 
technologies, Carlsbad, CA) overnight at 4°C. Smaller biopsies or cut biopsies were 
incubated a shorter time, 4-6 hours leading to similar effect. Epidermis and dermis were 
manually separated and incubated with 4.5 mg/mL Collagenase III (Worthington, 
Lakewood, NJ) and 5µg/ml DNAse (Roche, Basel, Switzerland) for 90 minutes at 37°C. A 
cell suspension was obtained after mechanical disruption of the tissue by pipetting up and 
down for several 4-7 minutes (for 6mm dermis and for the epidermis) or using Medicon 
(for 4mm dermis) and filtration was done through a 100 µm first and then 70µm cell 
strainer (BD Bioscience). The preparation of cervix and gut samples was done similarly and 
detailed in PAPER I. 
Cell sorting 
Freshly isolated cell suspensions were stained and kept on ice before sorting. In PAPER II, 
Cell sorting into QIAzol Lysis Reagent (Qiagen) was performed using MoFlo XDP 
(Beckman Coulter) cell sorted, by CD45 and CD3 markers. In PAPER I and in the results 
part, skin cell suspensions were stained for CD45 CD4, γδTCR, CD3, CD103 and CD49a 
and PBMCs for CD3, CD4, γδTCR, CD45RA, CD62L and CLA and then sorted into 
Qiazol later RNA extraction, or Cell lysis Solution from Qiagen Puregene Kit (Qiagen) for 
DNA extraction. Sorted Qiazol-cell lysate were kept at -80 °C before extraction while 
lysate for DNA extraction were kept at 4 °C. Sorted cells were maintained in complete 
medium overnight before further experiments for the cytotoxicity experiments. TEM were 
defined as T cells negatives for CD45RA and CD62L. 
TCR sequencing (PAPER I) 
DNA Extraction and TCR Sequencing DNA was extracted (Puregene, QIAGEN) and the 
TCR-b CDR3 regions were sequenced and mapped (ImmunoSEQ, Adaptive Biotech). Data 
from productive reads were extracted from ImmunoSEQ platform for further analysis. Raw 
data were uploaded on the immuneACCESS platform provided by Adaptive- Biotech 
(doi.org/10.21417/B76K56). Details  
PMBCs isolation (PAPER I, II, III) 
Peripheral blood mononuclear cells (PBMCs) were prepared from 10-20 ml of peripheral 
blood using Ficoll Paque Plus (GE Healthcare) according to the manufacturer’s protocol. 
PBMCs were then either frozen in 1/1 volume of freezing medium (FBS with 20% DMSO) 
or cultured in Roswell Park Memorial Institute medium (RPMI) supplemented with 10% 
FBS and PEST for further experiments within 4 days. 
Cytotoxicity Assay (PAPER I) 
In brief, sorted and rested cell populations were used as effector cells against 51Cr-labeled 
P815 target cells supplemented with 0.5 mg/ml of anti-CD3 antibody (clone S4.1, 
Invitrogen) with effector-to- target ratios between 10 and 0.3. Samples were run in 
duplicates for 4hours at 37°C. 51Cr release in supernatant was measured on a g-counter 
(Wizard2, PerkinElmer) and specific lysis was calculated. 
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(doi.org/10.21417/B76K56). Details  
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Flow cytometry 
Freshly prepared cells were put in complete medium (RPMI supplemented with 10% FBS 
and PEST. Cell suspensions were stimulated same day or the day after with PMA (50ng/ml, 
Sigma for PAPER I, III, 200ng/ml in PAPER II) and ionomycin (1 µg/ml, Sigma) for 4 
hours in the presence of brefeldin A (Golgiplug, BD Biosciences) and stained at 4°C. 
Intracellular cytokine staining was performed after permeabilization, following the 
manufacturer’s protocol (BD Cytofix/Cytoperm). The entire sample was acquired using 
LSR II. 
Additional ethical permits were used for the PAPER I: 2012/1900-31/1, 2013/1377-31 
with updates 2015/1078-32 and 2015/2124-32. Extensive methods are available at 
openarchive.ki.se/xmlui/handle/10616/45045. 
3.4 STATISTICAL ANALYSIS  
In PAPER I, II, III, IV, statistical analyses and graphical illustration were performed with 
PRISM (v6, GraphPad) or JMP 12 (SAS). Heatmaps were generated by MeV: Multi 
Experiment Viewer (www.tm4.org/mev.html). Mann–Whitney U test or Wilcoxon 
matched-pairs signed rank test were used for testing independent or paired data. Linear 
regression was performed with PRISM. Correlations were determined using Pearson’s test. 
FlowJo V9.9 was used to analyse flow cytometry data. In PAPER II, Barnes-Hut t- 
distributed stochastic neighbour embedding (t-SNE) analysis of 13-parametric data was 
performed on live CD3+ T cells as described in (Schlums et al., 2018). For data analyses 
and graphical visualizations, the R packages Rtsne, plyr, Hmisc, gplots, MASS, ggplot2, 
grid and RColorBrewer were used (Wickham, 2011). Time-series analysis were performed 
for PAPER IV using the calculated log2-fold changes between lesional (or healed) samples 
compared to all non-lesional samples from each given timepoint. The fold-changes were 
averaged in the case where several comparisons were involved at a specific time point. 
Then, the log2 fold changes comparing that time point value to the previous time point, 
were obtained by using the formula log2(median(Fold change of comparisons at time 2)) - 
log2(median(Fold change of comparisons at time 1)). The values for the first time point 
(Day 7) were set to zero to emphasize the changes in time. The genes were then clustered 
into clusters with the k-means clustering method based on their timecourse behavior. 
Visualisation of the calculated log2 fold changes across the time points were created using 
the ggplot2 R package (Wickham, 2016), with genes colored according to their associated 
cluster. To study the biological schemes of genes in each cluster, over-representation 
analyses were performed using R package clusterProfiler (Yu et al., 2012), with adjusted p-
value cutoff of 0.05 and minimum gene set size of 5. The analyses determined whether any 
of the gene sets were associated to a cluster at a frequency greater than what would be 
expected by chance. The enrichment p-values were computed using the hypergeometric 
distribution and listed for each cluster. 
For the enrichment analysis presented in the results part, PARTEK Partek Genomics Suite 
software (Partek, St. Louis, MO) was used. For the three time-points Day 7, Month 2 and 
Year 2 of the ACD study, baseline samples were aligned with bowtie 2. One sample was 
excluded because of low alignment quality. The quantification was done with PARTEK 
E/M, normalization to TPM was done and annotation was performed using RefSeq. Lists of 
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DEGs were generated comparing lesional (or healed) to NL samples. Transcripts with p-
value <0,1 were subsequently used for enrichment analysis using gene lists previously 
published by Swindell et al (Swindell et al., 2016). These cytokine activity signatures were 
based on the identification of cytokine-responsive transcripts comparing exposed 
keratinocytes to non-exposed keratinocytes to cytokines in vitro, ranked by the p-value 
obtained comparing the stimulation to the control. The top 100 cytokine-induced or the top 
100 cytokine-repressed were used. Results were considered further usable if p-value <0.05.  
An additional dataset was used for enrichment analysis. RNAseq of T cell-subsets was 
generated after sorting of different subsets of circulating CD4+ and CD8+, CLA+ or CLA-. 
In the dermis, CD4 and CD8 T cells were sorted according to the presence of CD103 and 
CD69 on their surface, and in the epidermis according to their CD69, CD103 and CD49a 
status. Gene lists of the top 100 genes expressed in each subset were generated and used 
with the enrichment analysis function of PARTEK.  
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4 RESULTS AND DISCUSSION 
4.1 TRM FUNCTIONALITY  
4.1.1 CD49a defines a subset of CD8+ TRM cells poised to cytotoxicity  
Results: The expression of CD103 in CD69+ TRM cells is associated with a higher 
production of IFN-g in epidermis and IL-22 in the dermis in human (Watanabe et al., 2015). 
Using flow cytometry, PAPER I identified that the presence of the CD49a integrin on 
CD8+ TRM cells in the human epidermis was linked to stronger effector functions in terms 
of cytotoxicity and IFN-g production. In Fig. 2, RNA sequencing showed that epidermal 
CD8+CD103+CD49a+ T cells expressed more GZMB and IFNG and less CCR6 in 
comparison to CD8+CD103+CD49a- T cells. CD49a+ TRM cells required the presence of IL-
15 to swiftly produce Granzyme B and perforin (Fig. 3), and perform actual cell-killing 
(Fig. 5). Finally, functional dichotomy according to the CD49a expression was conserved in 
T cells extracted from vitiligo and psoriasis lesions, with CD8+CD103+CD49a+ cells poised 
to more IFN-g production than CD8+CD103+CD49- cells and vice versa regarding the IL-17 
production. In never-lesional psoriasis (NLP) and active psoriasis, CD49a- TRM cells 
accumulated in the epidermis and were more prone to IL-17 than CD49a+ epidermal cells 
(PAPER II, S. Fig. 4).  
Discussion: These data indicate that CD49a is a phenotypic marker of functional relevance 
in both healthy and diseased human skin. Of note, epidermal and dermal compartments are 
not exposed to the same dangers and may need different T cell protection. In healthy skin, 
the CD8+CD103+CD49a+ cells are primarily present in the epidermis. Several findings 
underscore that these cells could play a role in controlling skin malignancies. First, CD49a+ 
TRM cells that recognize melanocytes are enriched and activated in vitiligo, a disease that is 
correlated to a reduced risk as well as to good treatment response in melanoma (Hua et al., 
2015; Richmond, Strassner, Rashighi, et al., 2018). Second, CD49a+ TRM cells are situated 
close to their ligand collagen IV located at the basement membrane of both skin and blood 
vessels. This represents the optimal location for potential gatekeepers of the dermo-
epidermal zone and the venules, limiting the dissemination of the malignant cells. Third, 
their cytotoxicity would make these cells excel at eradicating tumor cells. In patients with 
disseminated melanoma subcutaneously vaccinated with a melanocyte-derived antigen 
recognized by T cells (Melan-A), the ratio of circulating CD8+ T cells expressing CD49a 
was correlated with better survival (Murray et al., 2016). To better understand the role of 
the CD49a T cells in the early steps of melanoma, the characterization of the CD49a status 
of T cells located close to in situ melanoma compared to invasive melanoma would be 
useful.  
CD49a is required for T cells to enter the epidermis, as exposed in 1.3.1.5. It is unclear 
whether CD8+CD103+ cells not harboring CD49a did not need this marker to penetrate the 
epidermis of if they have lost it after their entry. Whether the functional dichotomy between 
CD49a+/- TRM cells is acquired before or after the entry into the epidermis is also unknown. 
Determining the role of cytokine exposure or other local tissue factors in the expression of 
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TRM markers is an active field of research. Indeed, when the factors influencing the 
expression of the functional markers on TRM cells are known, it could open the way to 
marker-modifying interventions and hopefully permit to alter T cell function in the upper 
layer of the skin, to potentially control skin protective functions. 
 
4.1.2 Ex vivo activation of T cells in skin explants is a reliable method to study T 
cell-related tissue responses 
Results: To characterize the functional consequences of TRM cell-activation in human tissue, 
a method inspired by DiMeglio et al., was set-up (Di Meglio et al., 2014). One day after ex 
vivo TCR stimulation with the anti-CD3 OKT-3 in skin biopsies, the antibody was 
detectable on T cells in the skin (PAPER III, Fig. 1). An increase in IL-17 and IFN-g 
production was noted in T cells then extracted from the skin. This effect was maximal after 
one day and decreased progressively during the following days (not shown). After 72 hours, 
the tissue architecture started to be degraded in ex vivo cultures. Following 16-48 hours of 
culture and 4-8 hours of incubation in dispase, the purified mRNA was of reasonable 
quality (Result Figure 1A). Rapid upregulation of mRNA levels of chemokines and 
cytokines was obvious in OKT-3 stimulated tissues. To limit the tissue damage due to the 
incubation, the 16 hours timepoint was chosen for the following experiments (Result Figure 
1B). Many transcripts were up- or downregulated by OKT-3 exposure, as determined by 
mRNA sequencing, both in epidermis and dermis (Result Figure 1C). Those genes were 
taken into consideration in designing a custom panel of genes for RNA copy counting with 
Nanostring Technologies. The expression of classically epidermal genes (keratins, defensin) 
in the dermal activated samples after OKT-3 emphasized the difficulty to interpret dermal 
data since the hair follicles stay in that skin compartment during the dispase-driven 
separation of the epidermis from the dermis.  
Discussion: Likewise the tissue-wide transcriptomic changes observed in mice upon 
reactivation of virus-specific TRM cells (Ariotti et al., 2014), clear interferon-driven tissue 
responses were observed in human skin explants. This reflected the known production of 
IFN-g by epidermal and dermal T cells (Watanabe et al., 2015). This was clear in both 
epidermis and dermis despite the seclusion from the blood circulation. Three mRNA 
analysis methods, RT-qPCR, nanostring, and RNA-sequencing could confirm the main 
differentially expressed transcripts.  
In this thesis, the focus was on epidermal tissue responses instead of responses in the 
dermis that is richer in T cells. This has four explanations. The first is the few cell types 
present in the epidermis, namely keratinocytes, LCs, T cells, melanocytes that facilitate 
results extrapolation. Second, to ensure that the cells analyzed were not circulating, the 
non-vascularized epidermis was preferred to avoid blood contamination. Third, since 
residency cannot be directly tested in ex vivo samples, focusing the analysis on epidermis 
made it more probable that the cells observed were resident ones. The last additional 
technical reason lies in the anatomy of the skin. When separating epidermis and dermis, the 
hair follicle stays in the dermis. Thus, the dermal samples are a mix of dermis and hair 
follicles cells, while the epidermal sample is plain interfollicular epidermis.  
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Result Figure 1 Method development 
(A) Example of bioanalyzer output of one sample of mRNA from epidermis after the incubation of skin 
explants 16 hours with OKT-3 and thereafter separation of epidermis and dermis with dispase. (B) RT-qPCR 
of epidermal and dermal samples after incubation with OKT-3 or IgG2a, showing 2 timepoints. Housekeeping 
gene is beta2microglobuline, dot plot of the data visualized with the 2^-deltaCT method. (C) Dot plots of the 
RNA sequencing data, showing results from three healthy samples. 16h is 16 hours, 48h is 48 hours. 
 
 
 63 
  
 
Result Figure 1 Method development 
(A) Example of bioanalyzer output of one sample of mRNA from epidermis after the incubation of skin 
explants 16 hours with OKT-3 and thereafter separation of epidermis and dermis with dispase. (B) RT-qPCR 
of epidermal and dermal samples after incubation with OKT-3 or IgG2a, showing 2 timepoints. Housekeeping 
gene is beta2microglobuline, dot plot of the data visualized with the 2^-deltaCT method. (C) Dot plots of the 
RNA sequencing data, showing results from three healthy samples. 16h is 16 hours, 48h is 48 hours. 
 
63
 64 
4.2 RESIDENT T CELLS IN PSORIASIS 
4.2.1 Epidermal TRM cells in Never-lesional psoriasis differ from healthy skin  
Results: Psoriasis is a multifactorial disease with a genetic predisposition. The normal-
looking skin of psoriasis patients differs from healthy skin (Swindell et al., 2017; 
Chiricozzi et al., 2016). Whether the skin TRM cell population also differed remained to be 
shown. As circulating cytokines are modified in severe disease and might influence the skin 
cell compositions (Arican et al., 2005), we set up to characterize skin TRM cells in patients 
with mild disease. Confocal imaging identified a higher epidermal thickness and more 
numerous CD8+ T cells than in healthy skin (PAPER II, Fig. 3). Next, flow cytometry 
helped characterize the T cell subsets and their cytokine production. Two subsets prone to 
IL-17 production, namely CD8+CD103+CD49- cells and CD4+CCR6+ cells were more 
abundant in NLP compared to the healthy epidermis (Fig. 3G-H). Indeed, CCR6+IL17+ 
cells were more abundant in NLP epidermis, but not dermis, and around 10% of CCR6+ T 
cells co-produced IL17 and IFN-g (Fig. 4). An imbalance of IL-17+ and IL-22+ T cells in 
resolved psoriasis lesions had been described by the group (Cheuk et al., 2014), with Tc17 
and Th22 T cells retained in resolved skin after both biologics and light treatments. The 
cytokine production of resolved skin and NLP skin were compared. Cytokine-producing T 
cells were more abundant in the epidermis than in the dermis for both RP and NLP. Ratios 
of the cytokine production in NLP with RP to healthy skin showed that the percentages of 
IL-22+ cells among CD4+ and IL17+ cells among CD8+ TRM cells in NLP were intermediate 
between healthy and RP skin (Result Figure 2). 
Discussion: The non-lesional skin from psoriasis patients has long been suspected to be in a 
“pre-psoriatic” state and the T cells from NL skin are sufficient to develop lesional skin as 
presented in 1.3.1.5. In PAPER II, I added a functional description of those T cells in the 
NLP skin that can be incriminated in disease development with an increase in T cells 
producing IL-22 and IL-17 in NLP compared to HC epidermis. When a factor is increased 
in inflamed tissue, pathogenicity is often suspected but causality can be complicated to 
assess. Both IL-17 and IL-22 are considered pathogenic in psoriasis and the pathogenicity 
of IL-17 has been proven through the use of its inhibition as a treatment. However, the role 
of IL-22 is less clear (Le et al., 2019). In vitro, IL-22 drives proliferation of keratinocyte 
but IL-22 has homeostatic functions in barrier tissues (Eyerich et al., 2010) and in the gut, 
the lack of IL-22 from ILCs lead to the dissemination of gut bacteria. In conclusion in 
psoriasis, it is not yet clear whether the presence of IL-22 is a consequence of the tissue 
disruption by IL-17 or if it is actively aggravating the tissue pathology.  
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Result Figure 2 Differences in cytokine production between psoriasis and healthy skin T cells 
Skin biopsies were taken from patients untreated on lesional and never-lesional skin, in treated patients on 
healed skin, and on healthy donors. Epidermis and dermis were separated and skin cell suspensions were 
prepared. After both extra- and intracellular stainings, flow cytometry analysis was performed. (A) Dot plots 
of the percentage of live, CD3+, gdTCR- cells CD4+ T cells producing IL-22 (left) and CD8+ T cells producing 
IL-17 (right). (B) Same samples but dot plots of the ratio of the percentage of cytokine-producing cells in 
diseased skin over the percentage in healthy skin. * if p<0.05, ** if p<0.01, *** if p<0.001, **** if 
p<0.0001. NLP = never-lesional skin, BIO = treated with biologics (anti-TNF or anti-IL-12/23), UVB = 
treated by UVB, PP = lesional psoriasis.  
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4.2.2 Recruitment of CCR6+ T cells to the skin might be influenced by microbial 
exposures 
Results: Why certain subsets of TRM cells are preferentially recruited and stay in the NLP 
epidermis is not known. The vast majority of IL-17 and IL-22 producing T cells in NLP 
epidermis were CCR6+ (Result Figure 3A). As CCR6+ Tregs have been reported (Yamazaki 
et al., 2008; Voo et al., 2009), 3 donors and 3 NLP skin samples were stained with Foxp3 
but could not detect Foxp3+ T cells in either healthy or NLP epidermis (not shown). 
Microbes participate in the regulation of local immunity, and whether the exposure to 
certain microbial antigens could trigger the production of the CCR6 ligand CCL-20 in NLP 
skin was tested. Taken that IL-17 is a major anti-fungal defense system, focus was put on 
fungal products : Candida albicans (HKCA), Mannan from Saccharomyces cerevisiae (SC) 
and from Malassezia furfur (MF) as well as peptides P5 and P24 from Trichophyton 
rubrum (TR) that had been involved in skin delayed hypersensitivity in humans (Woodfolk 
et al., 2000, 1996) were added to skin explants overnight. RNA was purified from the 
epidermis and dermis. CCL20 expression was increased in NLP epidermis after exposure to 
HKCA and SC, but not MF and TR (PAPER II and Result Figure 3B). IL-17 induced a 
moderate upregulation of CCL20 in healthy and NLP epidermis, but the exposure of 
healthy epidermis to SC prevented the IL-17-driven upregulation of CCL20, while no such 
an effect could be observed in NLP (Result Figure 3C). 
Discussion: The enrichment of epidermal NLP in CCR6+ T cells is striking, as is the 
increased cytokine production by this subset. Incriminating skin’s previous antigen 
experiences in the development of the resident T cell subsets is tempting, and that includes 
the microbiota. Previous work showed that bacteria on the skin can modulate its T cell 
population and shed light on the mechanisms involved (Naik 2012; Naik et al., 2015). 
Trying to understand the recruitment of CCR6+ T cells to the NLP epidermis, a difference 
in the response of NLP epidermis to fungal antigens compared to healthy skin was 
identified at the RNA level. The cell type producing CCL-20 could, however, not be 
determined. A modification of the Dectin or TLR expression by keratinocytes is possible, 
as well as the participation of LCs. Less probable, direct TLR-driven detection of SC by the 
T cells might also be possible. Independently of the molecular mechanisms, the global skin 
sensing system to common antigens seems modified in psoriasis. Additionally, our data 
suggested an immunomodulatory effect of SC on the healthy epidermis. Other antigens 
implicated previously in psoriasis pathogenesis could be tested in a similar setting, such as 
peptides containing the ALEEAN amino-acids found in the streptococcal M protein, 
Melan-A or LL-37 (Valdimarsson et al., 2009; Prinz 2004; Morizane and Gallo 2012; 
Arakawa et al., 2015).  
A recent report showed that the accumulation of CD8+IL-17+ TRM over CD8+IFN-g+ TRM 
cells in the NLP epidermis was correlated with disease duration (Vo et al., 2019). These 
findings and ours suggest a progressive accumulation of cells with disease-triggering 
capacities that could be driven by an inadequate response to skin commensals. 
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Result Figure 3 Fungal antigens trigger a CCL20 epidermal signal that could participate in the 
attraction of CCR6+ T cells to the skin 
(A) Flow cytometry analysis of skin T cells based on the cytokine-positivity. On the right, pie charts of the 
contribution of CCR6+ T cells to the cytokine production. Stars highlight the population statistically different 
between HC and NLP. (B) Heat map of the fold change of gene expression (RT-qPCR) after exposure to 
different fungal products, mean per group is used, 4-8 patients per group. No Log2 transformation. (C) Dot 
plot of the expression of CCL20 (RT-qPCR) after exposure of skin to IL-17 +/- SC or MF. Net changes are 
expression changes compared to samples not exposed to IL-17. HC is healthy controls, NLP is never-lesional 
psoriasis. SC, MF, HKCA, P5 and P24 refer to fungal antigens explained in text. For RT-qPCR, housekeeping 
gene is beta2microglobuline, dot plot of the 2^-deltaCT method. * if p<0.05. 
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4.2.3 T cell-activation In NLP triggers Type 1 interferon responses, potentially 
through the effect of Type 2 interferon on keratinocytes 
Results: In PAPER II, NLP keratinocytes overexpressed Myxovirus 1 (MX1), a proxy used 
for the presence of Type 1 interferon, compared to healthy cells (Fig. 2B-D). The activation 
of T cells in biopsies using OKT-3 further increased MX1 in NLP epidermis and in resolved 
psoriasis epidermis during treatment with biologics. MX1 was upregulated by both Type 1 
and Type 2 interferons (Fig. 2D) and IFN-a could be detected in keratinocytes supernatants 
after exposure to IFN-g. NLP epidermis contained a higher density of CD4+ IFNg+ T cells 
than in healthy epidermis, and a higher proportion of CD4+CCR6+ T cells produced IFN-g 
in NLP epidermis (Result Figure 3A above).  
Discussion: IFN-a has been involved in the early development of psoriasis lesion, based on 
arguments developed in the introduction page 42. No increased population of pDCs in the 
NLP skin was found (PAPER II Fig. 2C). This might be due to the low inflammatory state 
of our never-lesional skin that was sampled from patients with mild disease, far from the 
lesion whereas Nestle et al took samples immediately outside the clinical edge. The data 
presented in the thesis add an alternative mechanism that could explain the early presence 
of keratinocyte-derived IFN-a in the psoriasis skin, induced by IFN-g from TRM cells. 
Additionally, Tregs were recently proposed in a mouse model of psoriasis as another 
biological pathway of IFN-a control, as their absence led to an unabated release 
from macrophages (Stockenhuber et al., 2018).  
OKT-3 activation triggered strong pro-inflammatory signals in NLP explants. It raises the 
question of the underlying regulation that prevents disease development despite the pro-
inflammatory poising. Contrary to the dermis where many immune cell-types can reside, 
few are found in the epidermis, and it is conceivable that this control would come from T 
cells themselves. The techniques that were used to activate T cells might have shut off 
regulatory mechanisms. PMA bypasses co-stimulatory mechanisms and OKT-3 stimulation 
might overrule the effect of for instance PD1 that can be expressed on both human and 
mouse TRM cells (Gamradt et al., 2019; Kumar et al., 2017; Z. Wang et al., 2019). One 
clinical argument for the role of PD1 in psoriasis control is the development of psoriasis in 
patients treated with anti-PD1 (Bonigen et al., 2017). Overall, the genetically or 
epigenetically-driven peculiarities of keratinocytes from psoriasis patients combined to a 
different T cell balance in the skin have together the capacity to poise the tissue toward 
psoriasiform responses.  
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4.2.4 The tissue responses to T cell-activation in resolved psoriasis indicates the 
time before relapse 
Results: Both NLP and resolved psoriasis (RP) differ from healthy skin in terms of TRM cell 
subsets and functions. In PAPER III, T cell activation in skin biopsies collected from 
patients after different treatments for psoriasis was performed. A common feature RP skin 
was IL-17-related epidermal tissue-responses to T cell activation (Fig. 3, Fig. 4), whereas 
the IFN-related responses CXCL9 or CXCL10 were upregulated in healthy skin, active, or 
resolved psoriasis. Next, the balance between IFN-g and IL-17 responses upon T cell 
activation was assessed to test if such analysis could help predict the clinical outcome in 
patients. Resolved skin was sampled at the end of a UVB regimen, and T cells were 
activated in the biopsies using OKT-3. The balance between IFN-g-related responses 
(CXCL10) and IL-17-related responses (DEFB4A, SPRR2A, SPRR2B) correlated to the time 
before relapse as defined by the need to start UVB again or other systemic therapies.  
Discussion: The findings show that the interplay between the resident T cells and the 
surrounding stroma could have clinical use. To this day, the skin transcriptome was often 
offered as a potential predictor of treatment-response, but not as a relapse-predictor. One 
tool that was reported as capable to predict the disease relapse is Koebner phenomena, 
which refers to the formation of a psoriasis lesion at the site of skin injury. The reverse 
phenomenon is also observed, in which an injury on a psoriasis plaque results in a healed 
spot on the skin (Eyre et al., 1982). Patients not experiencing Koebner and patients 
experiencing the reverse Koebner experienced an improvement of psoriasis over a 6-month 
follow-up (Eyre et al., 1982). Skin trauma might impair the usual tolerogenic mechanisms. 
This interesting observation could also be due to a high systemic inflammation as the 
psoriasis area severity index (PASI) is correlated to the increase of certain circulating 
subsets of immune cells (Luan et al., 2014; Eysteinsdóttir et al., 2013). Hence, a tissue 
disruption could be enough to recruit TEM to the skin, especially if circulating clones 
recognized skin local antigens (Muschaweckh et al., 2016). If confirmed in future studies, 
this tool to predict disease flares could be a valuable addition in clinical practice for 
dermatologists. 
Previous work from the laboratory showed that TRM cells producing IL-22 and IL-17 were 
retained in healed epidermis from psoriasis patients (Cheuk et al., 2014). Here, activating T 
cells in healed skin led to a stronger IL-17 signal than in healthy skin, which was expected 
from the TRM population. This indicates that the functionality of the cellular infiltrate 
correlates to its effect on the surrounding tissue upon activation. 
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4.3 RESIDENT T CELLS IN ALLERGIC CONTACT DERMATITIS 
4.3.1 Transcriptomic analysis of ACD epidermis shows the persistence of a 
discrete disease signature up to two years after the resolution 
Results: In ACD, exposure to the allergen leads to a clinical relapse within days. Skin 
samples were collected at day seven after epicutaneous testing and after a 2-month 
exclusion of the allergen. Four patients were included from an additional cohort that had 
been exposed to the allergen for another study two years ago (Yazar et al., 2015). All 
patients had ACD to methylisothiazolinone (MI) (MI-ACD). Lesional or healed skin were 
compared to NL skin from the same patients taken simultaneously. RNA sequencing 
illustrated in Result Figure 4A showed that the number of transcripts up or downregulated 
progressively decreased with time. Two years after the cessation of symptoms, there was 
nevertheless several dysregulated transcripts. Enrichment analysis was performed using 
data from previously published studies in which keratinocytes were exposed to various 
cytokines mixes. Looking for which cytokine-signatures were embedded in the 
transcriptome and were most likely to explain the observed changes in our samples, the 
number-one driver of the transcriptional changes was IFN-g at day 7, replaced by TNF and 
IL-17 after 2 months after resolution (Result Figure 4B). Enough skin material was not 
available for flow cytometry characterization of TRM cell-subsets in the skin. Instead, “in 
silico dissection” using enrichment analysis based on previous RNAseq data of TRM cells 
subsets from healthy skin was performed using the ranked transcripts expressed in different 
TRM cell-subsets. Neither circulating cell nor dermal TRM cell-signatures appeared after 2 
years of disease resolution. Instead, the signature from CD4+ epidermal T cells seemed to 
faintly persist (Result Figure 4C). 
Discussion: The characterization of TRM subsets is lacking in human ACD. Although TCR 
analysis shows the long-term persistence of clonal T cells (Gaide et al., 2015) in healed 
ACD, the transcriptome is normalized 4-8 months after the active disease was resolved 
(Gulati et al., 2014). ACD is not clinically known to disappear fast, however, it is 
conceivable that TRM cell attrition happens to such an extent that their clinical relevance is 
uncertain, as shown in mice (Gamradt et al., 2019). Our data suggest that the epidermal 
transcriptome is not fully normalized two years after the withdrawal of the antigen, with 
persistent upregulation of S100As transcripts. However, the small sample size in this study 
warrants caution. Our setting differs from Gulati et al, as epidermis was separated from 
dermis before snap freezing. The findings may, therefore, illustrate differences in 
wounding-reactions between healed and non-lesional skin rather than a baseline expression. 
Indeed, the epidermis has an “inflammatory memory” that participates in subsequent 
wound repair independently of TRM cells (Naik et al., 2017). This epidermal memory was 
associated with epigenetic changes in epidermal stem cells. Therefore, the molecular scar 
identified in ACD could only partly be due to the T cells generated during ACD two years 
earlier and a disease memory might also lie in keratinocytes themselves. 
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Result Figure 4 Transcriptomic analysis in ACD up to 2 years after the cessation of exposure 
Biopsies were taken at day 7 (second reading of patch-test), 2 months and 2 years after the diagnosis and the 
eviction of the allergen methylisothiazolinone. Epidermis was separated from dermis and mRNA was purified, 
and sequenced. (A) Volcano plots of the Transcripts Per Kilobase Million (TPM) of dysregulated transcripts 
between lesional vs non-lesional or healed vs non-lesional (Log2FC <-2 or >2). (B) Enrichment analysis 
generated with PARTEK, using gene sets previously published where keratinocytes were exposed to cytokines 
and gene lists from upregulated or downregulated genes by these cytokines were generated (Swindell et al., 
2016). The top 100 upregulated were used to generate the red bars and the top 100 downregulated genes to 
generate the blue bars. Red bars show the enriched cytokine signature present in upregulated genes from our 
data. Blue bars show the enriched cytokine signature present in downregulated genes from our data (C) 
Heatmap generated with MeV, from enrichment analysis generated with PARTEK, where -log10 (p-value) is 
plotted, using gene set from TRM RNA sequencing data from the group, partly published in Cheuk et al., 
(Cheuk et al., 2017). 3-6 donors per group. a-EPI-CD8CD103+CD49a+; b-EPI-CD8 CD103+CD49a-; c-EPI-
CD4CD103+CD49a-; d-EPI-CD4 CD103-CD49a- ; e-DER-CD8 CD103+CD49a- ; f-DER-CD8 CD103-
CD49a- ; g-DER-CD4 CD103+CD49a- ; h-DER-CD4CD103-CD49a- ; i-CD8CLA+TEM ; j-CD8CLA-TEM; k-
CD4CLA+TEM ;l-CD4CLA-TEM.  
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4.3.2 The elicitation of ACD in skin explants two years after disease resolution 
triggers responses capable of matrix-disruption 
Results: The role of skin T cells in the ACD relapses is discussed in humans, and shown in 
mice (Gaide et al., 2015; Gamradt et al., 2019). In PAPER IV, using both RNA 
sequencing and Nanostring Technologies, the exposure to the allergen could elicit potent 
tissue-responses up to two years after resolution (Result Figure 5A-B). Transcript 
dysregulations were absent or much milder in NL skin than in healed skin (Result Figure 
5C). Among the top 100 genes upregulated in each group of samples, 30 were common 
between MI or OKT-3 exposure and specific to the healed epidermis, indicating an overlap 
between the allergen-specific responses and the effect of bulk T cell activation (Result 
Figure 5D). Among these genes, MMP12 was one that was also detected in lesional skin 
(Result Figure 5B). MMP-12 from macrophages has been associated with disease severity 
in a mice model of hypersensitivity, as mmp12-/- mice were protected from the development 
of symptomatic skin allergy (Meguro et al., 2016; Nakagomi et al., 2015). When testing 
MMP-12 activity on collagen IV and I, the collagen was degraded in a dose-dependent and 
time-dependent manner (Result Figure 5E and data not shown) (Taddese et al., 2010; 
Gronski et al., 1997). Thus, the allergen-specific skin memory had the potential to trigger 
matrix-degradation, both at the basement membrane with collagen IV and in the dermis 
with collagen I.  
Discussion: The in-depth analysis of a small patient group in which ACD was elicitated in 
skin biopsies uncovered mechanisms of disease memory. Part of the MI signature was 
specific to healed skin (MMP12, IL22), but others overlapped with non-lesional skin 
(CXCL10, CXCL11). The upregulation of CXCL10 and CXCL11 was expected after OKT-3 
as part of the core response to T cell activation as shown in PAPER III. The upregulation 
of these same transcripts by MI in non-lesional skin at month 2 was more intriguing and 
could reflect that TRM cells had seeded to other sites of the skin, a phenomenon that is 
known in mice, especially in case of repeated exposures and minor local trauma 
(Muschaweckh et al., 2016b; Davies et al., 2017). The differences observed between the 
Month 2 and Year 2 disease memory might depend on several things. First, the TRM cells 
might progressively disappear. Second, the antigen might still be present in the skin at 
month 2, perpetuating the T cell settlement locally, but not at year 2. It was shown in mice 
that allergens could persist in the skin more than a month after the exposure (Gamradt et al., 
2019). Third, the type of exposure to the allergen differed substantially, as one group was 
sampled on healed skin after a patch-test (high concentration, 48h under occlusion) and the 
other after a weeks-long rinse-off study. I tried to control for these differences by 
intraindividual sampling of healed and non-lesional skin.  
Exposure of resolved skin to MI did not totally phenocopy active ACD. MMP12 was one of 
the transcripts that were both upregulated in the lesional ACD skin and after elicitation in 
healed skin. MMP12 expression could help discriminate eczema from psoriasis (Quaranta 
et al., 2014), and the protein has primarily been detected in macrophages but can also be 
expressed in keratinocytes (Kulig et al., 2016), like in lupus skin examined with 
microscopy (Manetti et al., 2012). The increase of MMP12 could relate to IL-13 and IFN-g 
exposure in keratinocytes but it is not part of the top upregulated genes upon exposure of 
healthy keratinocytes to common cytokines (Ramalingam et al., 2016; Swindell et al., 
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2016). From these data, it is arduous to conclude on the pathogenicity of MMP-12. 
Degradation of collagen can favor the entry of inflammatory cells, thus increasing the 
inflammatory infiltrate. But MMP-12 could also be fulfilling other functions such as 
cytokine cleavage or promoting fibrosis (Dufour et al., 2018; England et al., 2011). A more 
thorough characterization of its role in the skin is needed. 
 
 
Result Figure 5 Tissue responses to ex vivo elicitation of CD in skin explants 
(A) Experimental setting. (B) RNA was purified and sequenced from epidermal samples after incubation of 
whole skin biopsies in MI, OKT-3 or the control. Volcano plots of Transcripts Per Kilobase Million (TPM) of 
dysregulated transcripts between MI-exposed and control (IgG2a). (C) Bars of the quantitative validation of 
RNA sequencing finding, using Nanostring Technologies. (D) Venn diagrams generated with JMP, of top 100 
upregulated transcripts between MI or OKT-3-exposed and non-exposed healed and non-lesional samples, 
using RNA sequencing data, for each group stated in the figure. (D) Dot plot of the collagen degradation after 
exposure to MMP-12 at different concentration during 48 hours. MI = Methylisothiazolinone, NL = Non-
lesional, FC = Fold change, Les = lesional, control = IgG2a  
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4.4 ETHICAL CONSIDERATIONS 
• The experiments performed for this thesis involved human sampling. The patients 
don’t directly benefit from the research and are exposed to potential side-effects 
after the sampling, such as skin infection, thus restricting the number of patients 
included and the number of biopsies taken for each patient. 
• Another consideration is the relationship with the patient while sampling as patients 
may agree to participate in the research also because it grants them quick access to a 
dermatologist. It is a problem as the dermatologist taking research samples is 
usually not the one in charge of the patients’ follow-up. This lack of continuity 
might lead to suboptimal care. We tried to consider that when meeting the patients 
and choosing a medication.  
• One last problem relates to the number of patients that are sampled. Competing 
interests are at play: the first is to use as few samples as possible to decrease the risk 
of side-effects and not waste human material; the second is to make sure that data 
collected are enough to lead to new medical knowledge. This point is always 
considered when choosing the number of patients to samples for a given project and 
we tried to make sure all samples were used wisely and in the best possible way.  
4.5 MAIN LIMITATIONS 
• Skin explants permitted a compartmentalized analysis of the skin, with respect to its 
3D microenvironment, but the live visualization of the cellular interplay could not 
be visualized. We used confocal microscopy in complement to assess the cellular 
contacts. 
• The healthy donors underwent surgery, were more often women and were younger 
than the psoriasis patients that were recruited, thus making our control group 
imperfect. We tried to use non-lesional skin from the same patients as control. 
Ongoing studies focus on the relationship between age and TRM cell-subsets.  
• The techniques used in the generation and analysis of mRNA sequencing data were 
not part of the established competences in the laboratory. We chose to outsource 
analysis to the external companies to ensure a high level of expertise.  
• Over the years, dozens of patients were sampled, but only a few samples were used 
for each experiment, leading to a lack of power, and sometimes the absence of 
meaningful statistical comparisons. Whenever possible, we have tried to collect 
enough samples to ensure relevant statistical comparisons.  
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
In human skin, functionally distinct TRM cell-subsets are altered during inflammatory 
skin diseases. 
The functional dichotomy uncovered in PAPER I was based on the surface marker CD49a. 
It was conserved in common inflammatory skin diseases as CD8+CD103+CD49a- that are 
prone to IL-17 production were enriched in lesional and non-lesional psoriasis. Together 
with the work of other research teams, the data exposed in this thesis proposes CD49a+ TRM 
cells as a good target for further pharmaceutical development in the field of vitiligo. The 
cytotoxic capacities of CD8+CD103+CD49a+ TRM cells suggest a potential use in dermato-
oncology. The blossoming single-cell techniques will most likely help identify further 
disease-relevant functional subsets. 
In skin that has never been affected by psoriasis, TRM cells differ in composition and 
functionality.  
In addition to the genetic predisposition of NLP keratinocytes, an imbalance in skin TRM 
subsets poises NLP skin to psoriasis development. As shown in PAPER II, a microbe-
driven mechanism could participate in the accumulation of CCR6+ T cells in the epidermis. 
This calls first for a deepened study of factors allowing TRM survival and replacement in 
non-lymphoid tissues, and later on to microbe-based local treatments, reshuffling the TRM 
cell subsets in NLP and preventing disease development. However, a better knowledge of 
skin microbiota has to be reached first. A major question remains. If the whole skin of 
psoriasis patients is predisposed to the disease, how are plaques arising only in certain spots 
and not on the entire body surface? There, I hope that a joint effort of the psoriasis research 
community will uncover skin regulatory mechanisms in never-lesional skin that will help 
explain the focal control of psoriasis development. 
In resolved psoriasis skin TRM cells are capable to initiate tissue-responses relevant to 
clinical practice. 
TRM cells retained in resolved psoriasis can release cytokines that are amplified by stromal 
cells into potent tissue-responses in both skin compartments, although they correlated to the 
disease outcome only in epidermis. If validated in further studies, the findings of PAPER 
III pave the way for the development of a relapse predictor applicable to clinical practice. 
This also opens perspectives for other chronic inflammatory diseases. For instance, in 
patients with successfully treated inflammatory bowel diseases, the question about 
treatment withdrawal is arising. When to stop–and when to restart–a treatment are highly 
relevant questions for clinicians and patients, and tools deciphering the stroma—TRM 
interplay could be translated to chronic inflammatory diseases in several organs. 
In resolved allergic contact dermatitis, allergen-specific TRM cells provoke tissue 
responses with matrix-degrading capacities 
The data presented in PAPER IV show the existence of a long-lasting disease memory that 
is capable of rapid tissue responses upon allergen exposure, with the release of immune cell 
recruitment signals and a matrix-degrading potential. There is still a lot to uncover in ACD 
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compared to psoriasis and direct translation into clinics are more difficult to foresee. In 
particular, the characterization of the cellular functions of TRM cells in ACD is lacking. In 
situations where the avoidance of the allergen is impossible, strategies limiting the 
establishment of TRM cells or the tissue protein-licensing could be of interest. Whether our 
findings of matrix-degrading potential upon ACD elicitation can be translated to atopic 
dermatitis relapses remain to determine. In that case, early blockade of metalloproteinases 
might be of use in the early phases of local flares in moderate forms of atopic dermatitis, to 
limit symptoms. 
 
 
Figure 18 Answers to the research questions 
In conclusion, functional subsets of TRM cells that were identified in human skin were 
imbalanced in T cell-driven inflammatory skin diseases. Their interaction with stromal cells 
inside the skin microenvironment created disease-specific tissue-responses (Figure 19). 
Epidermal tissue responses appeared more pathogenic than dermal ones, echoing the 
preferential epidermal enrichment of TRM cells with pathogenic potential. Local treatments 
displacing the pathogenic skin TRM cells could improve the T cell-driven disease evolution 
hopefully by limiting local relapses and the development of focal inflammation. The last 
decade brought great technological advances and it is nowadays possible to perform multi-
omics analyses on a few square-millimeters of human tissues and observe human cell 
crawling in skin biopsies. I am confident that major discoveries can be done using human 
samples, in collaboration with patients. 
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Figure 19 Proposed inclusion of the thesis findings in the physiopathology of psoriasis and allergic 
contact dermatitis 
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First and foremost, I’d like to express my gratitude to the patients who participated in this 
work. I am ever surprised by the generosity and trust of Swedish people towards research, 
and I am deeply thankful for that. I only dared to take these tiny parts from your body 
because I believe it will be useful for others at some point. I hope I’m right. 
Liv, your parents were very inspired when they named you, you are a lively and grandiose 
human being. I like to think of you as the Amanda F. Palmer of science (maybe a bit far-
fetched, but your passion is contagious and forces respect). You’re doing a great job, 
although you do work too much. I am very proud to have contributed at my little level to 
your research, thank you for your time, trust and support. It was also nice to see your kids 
grow up for some years, and please thank Martin for the help with the thesis. Suzanne, 
you are a tough and excellent scientist and I am extremely thankful for your help on the JID 
paper, this was going kind of south before you intervened. I am happy that I learned to 
know you and stopped being a little afraid of you. Misi, thank you for your help in the 
contact dermatitis project, for the patients’ recruitment and afterward and for reading the 
thesis. I hope you are enjoying life far from the capital! Mona, if not for you I wouldn’t 
have made it to the skin clinic in 2013, for that I am forever indebted. You are a model of 
research leader to me. I observed you, your social smoothness, your classy mixture of 
kindness and cynicism, trying to understand how you do it. I haven’t figured it out yet so I 
hope we can keep in touch.  
To the Eidsmo group and collaborators. 
Kerstin, thank you for the time together in the lab, you are the epitome (yes that is actually 
a word) of what I like in people. Competent, smart and rational mind, respect and caution 
when expressing beliefs, empathy and irony. I think you know how much I like you and I 
enjoyed working with you. Stanley, thank you for your unwavering logical mind, your 
scientific knowledge and your technical masteries. You set the level (high) in this lab, that’s 
good. You are a very enjoyable friend, and I miss you. You were also a challenging 
colleague, and I miss that as well sometimes. I keep in mind your remark about skin color 
being restrained to epidermis after all, during these long hours of skin splitting… I am 
looking forward to seeing the continuation of this very nice scientific opening of yours. 
Elisa, thank you for your company, your daily help. You have tons of qualities, including 
many of the ones I lack, which made working with you really pleasing and comfortable. 
You are extremely competent and I often trusted you more than myself. You and Hanno are 
precious and I hope your world-traveling will bring many occasions to see each other. I am 
proud and happy that you’re staying in the psoriasis field for a while. Also, thank you for 
SOA. Elena, this is where thankfulness goes over to debt. I really don’t know how this 
thesis would have looked like hadn’t you show up. I will never thank you enough for all the 
work you’ve done, and your incredible energy and competence. I hope you are enjoying 
your Ph.D. I have not the slightest doubt that you will keep doing great in life, anyone 
would be blessed to have you by their side. Maxime, you made me realize I actually liked 
students. Even when they’re French! Or maybe I just liked you. Anyhow, thanks to you I 
could satisfy part of my curiosity for fungi. Ia, thank you for introducing me to the 
mannans world. You are an incredibly hard-working and tough woman and I admire you 
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years in your beautiful country and since you encouraged me so much to work with Liv.  
Bernt for your amazing kindness, you are a role model to me in everything from 
competence to lifestyle and the way you interact with people. Thank you for accepting to be 
my official mentor and for introducing me to your fantastic family. Natalia, for being so 
nice to me always, for teaching me so much, for the dedication you show to your work and 
your patients and for making sure we don’t forget culture in our daily life and listen to the 
sommarpratare and read good books. Toomas, for helping me in so many ways from the 
start, for knowing my country better than myself, and for your historical conversations. For 
accepting to take the hassle of this pemphigoid side-study, that was really nice of you. 
Peter, I learned a lot just by looking at you talking to patients at the ward, thank you for 
your tremendous and sometimes unexpected decision-taking abilities and your always 
entertaining anecdotes and ideas. Hassan, you’ve been a wonderful supervisor, you are too 
efficient and nice to be true, you must be an alien or something. Arne for taking care of me 
and help me fix the administrative hell. That’s something France and Sweden share but I 
think we still beat you when it comes to administrations driving people crazy. Thank you 
for teaching me about ISTs, one of my favorite topics in dermatology. Janne, for being 
such a kind, curious and amazingly good dermatologist and dermoscopist. Everything I 
know about that I learned from you. Maria K., for being this very competent (and far too 
modest) doctor and always being so kind and supportive. Lena L., thank you from the 
bottom of my heart for taking me in, maybe a bit reluctantly but in the end, I dare to think it 
was a win-win. Thank you also for letting me progressively spend all my time in the lab 
without a single time making any reproach, this is truly unbelievable. Hanna, Vera, Anna, 
Helena, Lena (both of you), Malin, Ulla-Maria, Sven, Ann-Sophie, Suzanna, Suzanne, 
Ulf, and the ones whose names I forget here, thank you for making the skin clinic such a 
great place to work at. Erika and Martina for being the best help ever and translating my 
early broken Swedish into nice hospital reports. I wish I could have brought you home with 
me. Helena and Maria for the help and support, and providing freezer racks! Lots of 
competent people out there. Josefin, Mahsa, Louise, Desirée, Maria (there are many of 
you), Klas, Carl-Fredrick, Anders, Magnus, Alice, Tove, Hannah, Lina, Anja, Johan, 
Nikki, Pontus, Harry, Kristina, Ebba, Lars, Peter, for your company through some 
weeks or several years, the nice lunches and keep lying about French accent being 
agreeable to listen to. All the others I don’t name here, thank you for all contributing to the 
good working environment.  
Now for the time-traveling. Lars A., Marie H., for your roles in my first research 
experience at KI back in 2009. Malin, Nina, you taught me Swedish over (many) fika back 
then and I am happy we became friends. Linus for accepting to be forced into lake ice-
skating and mountain hiking and sometimes teaching me the Swedish that got me a job 
many years later. Elin and Isabel for sticking around, being such fantastic and supportive 
friends and telling me about the challenges of translation. Not sure I deserve you. 
Camille, Charlotte, Michael, Mathilde, Juliette, Choup et bébé Constance, Catherine, 
Sofiane et Audrey, Julien, Philippe et Marguerite, Nico, Léa, Coline, Cédric, Aïssa, 
Philippe, Christelle, Riou pour vos visites en Suède, votre curiosité et avoir incarné un 
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moment la vitesse du temps qui passe. Paul pour un bon break rando norvégien qui m’a 
rendue encore plus attachée à la Scandinavie… 
Thank you, Stockholm, for being this beautiful city. I’ve known you for 10 years and I 
keep falling in love with you. I miss your light. Thank you, Sweden, for welcoming Lucas 
and me and bringing us probably some of the happiest years of our life. Thank you for your 
generous and wild nature. Please, Lappland, don’t get too hot and burn down, that would 
just break my heart. 
To the French dermatology society (SFD) for financial support. The Ecole de l’INSERM 
for having nourished this early research interest and for its support through the (14) last 
years. Thank you Frédéric Caux for the past and present support. A special mention to 
Benoit Funalot and colleagues from my current internship in genetics, for giving me this 
level of freedom. This would have been a very different thesis preparation without your 
support. 
A virtual thanks to Alma Moon Novotny (Rice University) for her comforting words on 
cytokines in the immunology EdX online course:  
“And you remember the stuff we had with complement? You remember the stuff we had with 
CDs? It's that same awful thing all over again. And again, the numbers tell the order in 
which it was discovered. They don't tell you anything about it. All I can do is apologize in 
advance for immunologists' complete refusal to make their naming system accessible to the 
average person.  
This is just something we live with.” 
The final thanks to the family. 
To my mum Yolande, for your unshakable trust, generosity, and love, I moved far away 
and you didn’t complain, you even found the nicest company in Claude and we had very 
good times during your repeated stays in Sweden. My bigger sister Anne-Claire, my model 
since my very first day, thank you for setting the standards high. You are the smartest 
person I know and I am confident you’ll find what you’re looking for. Julien, thank you for 
coming by in Sweden, even though it was in march and therefore not the bear-watching 
season. To my dad Pierre who left this world long ago but managed before that to set the 
stage regarding hard work, knowledge, values, and love. 
Lucas, thank you for this journey together. You are a wonderful man, and I am very proud 
to see that in addition to a leviathan of intelligence, general knowledge, energy, and hard 
work, you became an obstinate scientist! Thank you for believing in me so much, and for 
your caterpillar-style forward-pushing of everyone crossing your path, I included. Not sure 
what we’ll do next, but we’ll have many more great years together for sure, and as the song 
goes “Home is wherever* I’m with you. 
 
 
 
 
*Except the South of France. 
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